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Tumour Necrosis Factor Alpha (TNFα) is central to the immunopathogenesis of 
inflammatory bowel disease. It is initially expressed on the cell surface as a 
trimer, membrane TNFα, and cleaved from the cell surface by TNFα Converting 
Enzyme (TACE) to release a soluble trimeric form of the cytokine (sTNFα). 
Infliximab, an anti-TNFα antibody revolutionised the treatment of IBD. 
However infliximab is ineffective in up to a third and nearly half of patients lose 
response to infliximab over time. As yet the mechanisms of action of infliximab 
are unclear, although the importance of mTNFα is emerging. 
The aim of the study was to establish whether pharmacological and endogenous 
TACE inhibitors change the expression of mTNFα with a reciprocal change in 
sTNFα and other pro-inflammatory cytokines. Additionally possible 
mechanisms of action of anti-TNFα antibodies were tested.  
The expression of mTNFα and sTNFα were measured with FACS and ELISA 
respectively in vitro and ex vivo in controls and IBD patients. The functional 
effects of infliximab and etanercept were explored using a TNFα transfected 
CHO cell line and peripheral blood and lamina propria mononuclear cells. 
Changes in receptor tyrosine kinase (RTK) phosphorylation as a result of TNFα 
neutralisation in IBD explants were determined using a RTK phosphoarray.  
A significant reduction in sTNFα and an increase in mTNFα were seen with 
some TACE inhibitors, without any change in other pro-inflammatory cytokines. 
Apoptosis was not seen with anti-TNFα antibodies in either the TNFα 
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expressing cell line or in PBMCs. The study showed for the first time that 
infliximab reduces phosphorylation of RTKs such as EGFR, FGFR, Eph as well 
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List of abbreviations 
 
ADAM17 A disintegrin and metalloproteinase 
ADCC Antibody Dependent Cytoxicity 
AJ Adherens junctions 
ATGI6LI Autophagy gene 16 Like 1  
APC Antigen presenting cells 
CARD Caspase activation and recruitment domain 
CD Crohn’s disease 
CDAI Crohn’s disease activity index 
CDC Complement Dependent Cytotoxicity 
CHO Chinese hamster ovary 
CRP C-Reactive Protein 
CSF Colony stimulating factor 
DMSO Dimethyl sulfoxide 
DC  Dendritic cell 
DSS Dextran sulphate sodium 
EDTA ethylenediaminetetraacetic acid  
Eph Erythropoietin producing hepatocellular 
Eph R Erythropoietin producing hepatocellular Receptor 
EGFR Epidernal growth factor receptor 
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ELISA Enzyme-linked immunosorbent assay 
FACS Fluorescence activated cell sorting 
FAE Follicle associated epithelium 
FGFR Fibroblast growth factor receptors 
FLT3 A receptor tyrosine kinase required for dendritic cell 
development 
FSC Forward scatter 
GALT Gastrointestinal associated lymphoid tissue 
GC Germinal centres 
GDF-1 Growth differentiation factor-1 
GI Gastrointestinal  
GM-CSF Granulocyte macrophage colony-stimulating factor 
HBSS Hanks’s balanced salt solution 
HER Heregulin is one of a family of ligands with tumour initiating 
potential 
HGFR Hepatocyte growth factor receptor 
HLA Human leukocyte antigen 
HRP Horseradish peroxidase 
IBD  Inflammatory bowel disease 





IGF-IR Insulin–like growth factor -1 receptor 
IL Interleukin 
Ins R Insulin R 
ITAM Immunoreceptor tyrosine-based activation motif 
JAK Janus Kinase 
LP Lamina propria 
LPMCs Lamina propria mononuclear cells 
LPS Lipopolysaccharide 
M Microfold 
MAP Mitogen-activated protein 
MAPK Mitogen-activated protein kinase 
M-CSFR Macrophage colony stimulation factor receptor 
MFI Mean fluorescence intensity 
MHC Major histocompatibility complex 
MMP Matrix metalloproteinase 
MLN Mesenteric lymph node 
MyD88 Myeloid differentiation factor 88 
NADPH Nicotinamide adenine dinucleotide phosphate-oxidase 
 32 
NFKB Nuclear factor kappa B 
NK Natural killer 
NLR Nod-like receptor 
NO Nitric oxide 
NOD Nucleotide-binding oligomerisation domain 
PAMP Pathogen associated molecular pattern 
PBMCs       Peripheral blood mononuclear cells 
PBS  Phosphate buffered saline 
PCR Polymerase chain reaction 
PDGFR Platelet derived growth factor 
PLC Phospholipase C 
PMA Phorbol 12-myristate 13-acetate 
PP Peyer’s patches 
PRR Pattern recognition receptor 
PSA Polyssacharide A 
RA Retinoic acid 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute-1640 
medium 
RTK Receptor tyrosine kinase 
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SCID Severe combined immunodeficiency 
SED Subepithelium dome 
SFB Segmented filamentous bacteria 
SSC Side scatter 
STAT Signal transducer and activator of 
transcription 
TACE Tumour Necrosis Factor Alpha 
converting enzyme  
TAM Tumour-associated macrophage 
TED Trans epithelial dendrites 
TGF Transforming growth factor 
Th1 T helper 1 
Th2 T helper 2 
Th17 T helper 17 
TJ Tight junctions 
TIMP Tissue inhibitors of metalloproteinases  
TLRs Toll-like receptors 
TNF Tumour necrosis factor 
TNFRI Tumour Necrosis Factor Receptor I 
TNFRII Tumour Necrosis Factor Receptor II 
Tregs T regulatory cells 
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TSLP Thymic stromal lymphopoietin 
UC Ulcerative colitis 





1 General Introduction 
1.1 The Intestinal Immune System 
1.1.1 The Gut Mucosal Immune System 
The gastrointestinal tract is the largest immune organ in the body and is 
responsible for absorbing nutrients as well as maintaining the integrity of the 
mucosal barrier to potentially harmful antigens and organisms. However, it is 
also important that tolerance is induced to both innocuous antigens to prevent 
potentially harmful and inappropriate inflammation as well as tolerance to 
commensal microorganisms that are required for digestive function (Mowat, 
2003). The cross talk of cells of the innate and adaptive immune system with the 
microbiome, in combination with the specialised properties of the cells in the 
intestine, all contribute to immune homeostasis. 
In the classic paradigm of mucosal immunity, responses are divided into 
inductive and effector sites against antigens from the gut lumen. Briefly, the 
inductive sites are the Peyer’s patches (PP), where luminal antigens are sampled 
by M cells and dendritic cells, and presented to naïve T and B cells. The 
sensitised cells migrate to the mesenteric lymph nodes (MLN), traverse the 
thoracic duct to enter the blood stream where they home to the intestinal lamina 
propria using specific adhesion molecules and chemokines. 
The glycocalyx forms the first physical barrier to the luminal contents of 
ingested nutrients and the microbiome. It is composed of mucus produced by 
goblet cells and anti-microbial peptides released by Paneth cells. The thick 
consistency of mucus traps microorganisms preventing their invasion. The 
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intestinal epithelium (IE), beneath the glycocalyx is a single layer of cells that 
originate from multipotent stem cells located within the intestinal crypt. The 
epithelial cells have a number of adhesive properties to maintain the barrier, 
such as cadherins, desmosomes and tight junctions (Garcia-Hernandez et al., 
2017). The epithelium absorbs nutrients and can produce cytokines and 
chemokines, which help maintain the balance between tolerance and 
inflammation. The selective permeability of the IE is achieved via the 
transcellular and paracellular pathways. The transcellular pathway operates via 
specialised transporter mechanisms located on the apical and basolateral surfaces 
(Kiela and Ghishan, 2009). The paracellular pathways are associated with the 
transport in the intercellular space between adjacent epithelial cells. It is 
composed of tight junctions (TJs) and adherens junctions (AJs), which form the 
apical junctional complex. Adherens junctions together with desmosomes are 
responsible for forming strong, adhesive, intercellular bonds (Baum and 
Georgiou, 2011). Permeability, on the other hand is determined by the TJs. Four 
integral transmembrane proteins have been identified; occludin (Furuse et al., 
1993), junctional adhesion molecule (JAM) (Martìn-Padura et al., 1998),  
claudins (Furuse et al., 1998) and tricellulin (Ikenouchi et al., 2005). The 
intracellular domains are anchored to the peri-junctional actomysin ring via the 
interaction with an intracellular protein such as zonular occludens (ZO) proteins. 
The extra-cellular component of the protein forms the barrier.  
The intestinal epithelium is composed of various cell types with specialised 
functions, namely enterocytes which are primarily involved in the absorption of 
nutrients; goblet cells, which contain trefoil peptide factors, important in 
intestinal repair (Taupin and Podolsky, 2003). Paneth cells, found at the bottom 
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of crypts, secrete antimicrobial peptides which regulate the gut microbiota as 
well as growth factors involved in maintenance of neighbouring stem cells. The 
epithelium also contains tuft cells whose function has previously been unclear, 
but has recently been shown to initiate type 2 responses to parasites by secreting 
IL-25 (Gerbe et al., 2016). IL-25 activates tissue resident group 2 innate 
lymphoid cells (ILC2s) to secrete IL-13 which acts on the crypt progenitor cells 
to promote differentiation of tuft and goblet cells (von Moltke et al., 2016).   
Finally, enteroendocrine cells sense nutrients (Gribble and Reimann, 2016). 
 Microfold (M) cells located within the epithelium play a vital role in the 
follicular associated epithelium (FAE) of Peyer’s patches. Peyer’s patches are 
organised into 3 regions namely the FAE, which consists of a single cell layer of 
epithelial cells adjacent to the intestinal lumen; the subepithelium dome (SED) 
underlying the FAE; and B cell follicles and T cells areas (Victora et al., 2012). 
Ten per cent of the epithelial cells are M cells (Kanaya et al., 2012). M cells are 
specialised phagocytic cells in the FAE, which capture luminal antigens and 
present them to the immune cells in the dome. M cells differ from other 
epithelial cells in that the glycocalyx overlying them is thinner making it easier 
for them to phagocytose antigens.  They also have an irregular brush border and 
smaller microvilli. They phagocytose and transcytose antigen across the 
epithelium where the antigen enters intraepithelial pockets beneath the M cell 
basolateral membrane which contains lymphocytes and mononuclear 
phagocytes. 
Mononuclear phagocytes are composed of dendritic cells and macrophages. 
There is a substantial overlap in the surface phenotype of DCs and macrophages 
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and differentiating between them can be difficult. For example CD11c and MHC 
class II are expressed by both macrophages and DCs. However the expression of 
CD64 and Flt3 can identify cells as macrophages, as opposed to CD64-, Flt- 
cells which are DCs (Bain et al., 2013). 
Macrophages are found in the lamina propria throughout the entire GI tract and 
are located predominantly close to the epithelium. They capture and destroy 
material breaching the intestinal barrier due to their location and their phagocytic 
and bactericidal properties (Smythies et al., 2005). Trans epithelial dendrites 
(TEDs) extend their processes into the lumen to capture antigen; although these 
cells were initially thought to be dendritic cells due to their expression of CD11c 
and MHC class II, it is now known that the trans epithelial dendrites originate 
from CXCR1+ macrophages (Niess et al., 2005). In the steady state intestinal 
macrophages are hypo responsive to cytokine and Toll-like Receptor (TLR) 
activation. CD103+ dendritic cells in the lamina propria promote Foxp3+ 
regulatory T cells in the presence of retinoic acid and TGFβ, whereas CD103- 
dendritic cells drive T cells to produce pro-inflammatory cytokines such as IL-6 
and TNFα (Ng et al., 2010). 
One of the cytokines produced by epithelial cells is thymic stromal 
lymphopoietin (TSLP) which exerts its biological activities by binding to IL-7 
receptor IL7Rα and the specific TSLP receptor resulting in the phosphorylation 
of signal transducer and activator of transcription (STAT)5  (Takai et al., 2012). 
TSLP promotes the development of tolerogenic dendritic cells in the lamina 
propria (Iliev et al., 2009) which induce the differentiation of naïve T cells into 
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Foxp3+ Tregs and block the development of Th1 and Th17 cells  (Rescigno and 
Iliev, 2009).  
Naive T cells are presented with microbial antigens either in the Peyer’s patches 
or in the MLN by antigen-loaded dendritic cells which have migrated to the 
MLN via the afferent lymphatics resulting in the priming and expansion of 
effector T cells. The primed T cells then exit the MLN via the efferent 
lymphatics, return to the circulation via the thoracic duct and home to the gut 
lamina propria.  
The trafficking of T cells to the appropriate organs is a highly regulated process 
mediated by members of the selectin, integrin and chemokine protein family. 
Selectins expressed on the endothelial surface and selectin ligands on the 
circulating leucocyte bind loosely, tethering the leukocyte to the endothelium. 
Chemokines activate integrins, which then form a tight bond to their specific 
adhesion molecules, which enables the extravasation of the leukocyte across the 
endothelium.  
Different combinations of chemokines and integrins are found in different parts 
of the body to ensure that leukocytes are recruited to the areas needed. Cells 
expressing CCR9 and α4β7 generated in the PP migrate back to the intestinal 
lamina propria. CCR9 binds to the ligand CCL25 that is preferentially secreted 
by the small intestinal epithelium (Bekker et al., 2015). 
The integrin α4β7 binds mucosal addressin cell adhesion molecule-1 
(MAdCAM-1). The expression of CCR9 and α4β7 is induced by dendritic cells 
in Gut Associated Lymphoid Tissue (GALT). Iwata et al., (2004) showed that 
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this was mediated by retinoic acid (RA), a metabolite of vitamin A. Vitamin A 
deficient mice have few T cells in the small intestinal lamina propria (Iwata et 
al., 2004). Retinoic acid also induces gut-homing IL-10 producing regulatory T 
cells (Bakdash et al., 2015). DCs in GALT express RALDH, the key enzyme in 
converting retinol into retinoic acid, while DCs at other sites do not.  Retinoic 
acid binds to cognate nuclear receptors which act as transcription factors to drive 
α4β7 and CCR9 gene expression. 
The epithelium also contains a large number of lymphocytes, mostly CD8+ T 
cells and is enriched in gamma delta T cells. These cells are thought to be able to 
kill virally infected epithelial cells.  Space precludes a detailed discussion of 
these cells because there is very little evidence they play a role in IBD. 
1.1.2 The Effector Site of Mucosal Immunity- The Lamina Propria 
The lamina propria is the effector site of mucosal immune responses. After 
interaction with APCs, T cells receive signals via their T cell receptors (TCRs), 
co-stimulatory molecules and a complex network of cytokine signals and 
undergo activation and differentiation from naïve T cells into effector CD4+ T 
cells. One of the most important signalling pathways, which transduce cytokines, 
is the JAK-STAT pathway (Soldevila et al., 2004). The pathway consists of the 
Janus kinase (JAK) proteins JAK1, JAK2, and TYK2 and signal transducer and 
activator of transcription (STAT) proteins one to six. JAK activation occurs 
following ligand binding to a cell surface receptor, which brings two JAKS into 
close proximity. This results in phosphorylation of tyrosine residues on STATS, 
which are latent transcription factors located in the cytoplasm.  The activated 
STAT enters the nucleus and activates or represses transcription of target genes. 
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This provides a mechanism to translate an extracellular signal into a 
transcriptional response. The suppressors of cytokine signalling (SOCS) proteins 
are inhibitors of STAT proteins by interacting with Janus kinases to prevent 
STAT activation. (Nicholson et al., 1999). 
The main types of effector T cell lineages are Th1, Th2, Th17 and Tregs and 
their differentiation is related to particular cytokines and transcription factors.  
1.1.2.1 Th1 cell development 
Dendritic cells secrete IL-12 on exposure to pathogens, which binds to the IL-12 
receptor on the naïve T cell, upregulates the Th1 transcription factor T- box 
expressed in T cells (T-bet), and down-regulates GATA3, the transcription 
factor for Th2 cells. IL-12 activates STAT4 signalling giving rise to the 
transcription and secretion of IFNγ. In addition Th1 cells secrete TNFα and IL-2 
to regulate cell-mediated immunity, such as to intracellular pathogens. T-bet 
expression is central in the balance between susceptibility to infection and 
autoimmunity. T-bet deficient mice are resistant to autoimmune diseases such as 
diabetes and colitis, but are more susceptible to mycobacterial and viral 
infections  (Powell et al., 2010). 
1.1.2.2 Th2 cell development 
Following CD4+ activation through the TCR, the activation of STAT6 by IL-4 
leads to the transcription of GATA-3 which results in the release of IL-4, IL-5, 
IL-10 and IL-13 which promote B cell function. IL-4/ STAT6 signalling in PP 
leads to class switching to IgA.  TGF-beta is also an Ig switch factor (Seo et al., 
2009). 
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1.1.2.3 Th17 cell development 
Th17 cells require TGFβ, IL-21, and IL-6 (rather than IL-17) (Bettelli et al., 
2006). Th17 cells produce IL-17 and IL-22 providing defence against 
extracellular pathogens. They express a specific transcription factor ROR 
gamma t. 
1.1.2.4 T regulatory cell development 
T regulatory cells are a population of T cells responsible for suppressing the 
proliferation of effector T cells and the production of Th1 and Th2 cytokines. T 
reg cells normally constitute 1-10 % of the T cell population. Natural T regs are 
thymus derived and are characterized by their expression of CD4, CD25 and 
have high expression of the transcription factor Foxp3. They are suppressed by 
both cytokines (ie IL-10) and contact dependent pathways (CTLA-4). Inducible 
Tregs are the CD4 subset, which become regulatory when they see antigen in the 
presence of TGFβ. They are also FoxP3+ and suppress by making TGFβ. Recent 
studies have shown that numbers of functional Tregs in the gut in IBD are the 
same as in normal gut, the high expression of smad7 in effector cells makes 
them resistant to TGFβ made by Tregs (Fantini et al., 2009). 
1.1.3 The Intestinal Microbiome 
The intestinal microbiome consists of up to 1013 microorganisms maximally 
concentrated in the colon (MacDonald et al., 2011b). These are made up of just a 
few main phyla, with the two most dominant being Bacteroidetes and 
Fermicutes, and at lower numbers of the phyla Actinobacteria, Proteobacteria, 
Fusobacteria and Verrocomicrobia (Eckburg et al., 2005). The proportions of 
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these are dynamic within an individual and vary between individuals depending 
on the type of birth, diet, age and antibiotic use. The microbiome consists of 
transient and permanent species depending on their ability to colonise the gut. 
Permanent microbiota have adapted to establish a mutual relationship with the 
host and do not usually survive as free-living organisms. These are true 
commensals. Transient microbiota on the other hand do not have a mutualistic 
relationship with the host but survive despite host defences. The effect can be 
innocuous, pathogenic or beneficial.  
Commensal bacteria are beneficial to the host by competing for space and 
nutrients within the lumen and thereby preventing other pathogenic bacteria 
increasing in numbers that could be harmful to the individual. The microbiome 
also provides nutritional benefits to the host such as synthesizing vitamins (Kau 
AL et al., 2011) and ferment fibre to produce short chain fatty acids, such as 
butyrate, which is a major energy source for colonocytes, and stimulates colonic 
blood flow and electrolyte exchange (Bhat and Kapila, 2017).  Butyrate is also 
an inhibitor of histone deacetylation which affects transcription of pro- and anti-
inflammatory genes (MacDonald et al., 2011b). However it is becoming 
increasingly clear that their presence is also vital in developing the gut immune 
system. Indeed germ free mice have small Peyer’s patches, and have very low 
numbers of T cells and plasma cells in their gut, which increases following 
introduction of microbes (Hooper et al., 2001). 
The intestinal microbiota influences mucosa and T-cell responses. T-helper type 
I (Th1) and Th2 cells control intracellular microorganisms and helminths 
respectively. Th17 cells protect the host from bacterial and fungal infections 
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(Ivanov et al., 2008). Ivanov et al., (2008) initially showed the direct association 
between the presence of a single microbe, the segmented filamentous bacterium 
(SFB), in the small intestine of mice and the accumulation of Th17 cells in the 
small intestine lamina propria, and their ability to mount effective Th17 
responses. Germ free mice have significantly impaired mucosal and systemic 
Th17 responses. Mice treated with antibiotics also show a reduction in Th17 
cells in the SI LP. The reduction in Th17 cells was inversely proportional to T 
reg cell numbers in the SI LP (Ivanov et al., 2009). 
SBF are different from other gut commensals in that they adhere to the ileal 
epithelium (Atarashi et al, 2015). Other bacterial species, which are able to 
adhere to the epithelium, are also able to induce Th17 cell responses. These 
include E.coli 0157 and Citrobacter rodentium (Atarashi et al., 2015). However 
mutant forms of E.coli 0157 deficient in a protein required for epithelial 
adhesion, called intimin, are unable to adhere to the IE and fail to induce Th17 
responses (Atarashi et al., 2015). 
Recent findings by Sano et al., (2015) demonstrate that the induction of Th17 
cells by SFB is due to the expression of a protein called serum amyloid A (SAA) 
protein 1 and 2 on epithelial cells in the ileum.  
The induction of T reg cells is associated with the non-pathogenic Clostridium 
clusters XVIa and IV (Atarashi et al., 2011). Treg cells of mice colonised with 
these clusters also contain a large number of Helios- Foxp3+ cells suggesting 
that the Clostridium IV clusters may induce colonic iTreg conversion. 
Additionally these cells also express high levels of CTLA-4 on their surface and 
make IL-10 (Atarashi et al., 2011). Round and Mazmanian, (2010) showed that 
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polysaccharide A (PSA), an immunomodulatory molecule produced by 
Bacteroides fragilis increases expression of IL-10 and requires TLR2 signalling. 
PSA has over the years been shown to have many apparently conflicting 
functions in the gut and its real role has not yet been discovered. 
1.1.4 Pattern Recognition Receptors (PRRs)  
PRRs recognise conserved structures of bacteria and viruses, called pathogen 
associated molecular pattern (PAMP)s, and alert the host to a potential infection. 
PRRs include transmembrane Toll-like receptors (TLR) and intracytoplasmic 
receptors such as NOD receptors. There are 10 TLRs and their distribution 
varies throughout the gut. TLR5 is basically expressed in the colonic epithelium 
and recognises invasive flagellated bacteria, whilst TLR2 and TLR4 are found 
predominantly in the colonic crypts. TLR3 is expressed in mature enterocytes in 
the small and large bowel (Elia et al., 2015). Alternatively NOD1 and -2, also 
known as CARD 4 and -15 are found in the cytosol of epithelial cells. Following 
injury or ulceration, PRRs are exposed to PAMPs such as lipopolysaccharide 
(LPS). Recognition of LPS by TLR4 and its co-factors CD14 and MD2 triggers 
signalling through MYD88 and results in NFκB and MAPK activation. Mice 
lacking either TLR2, TLR4, TLR9, or Myd88 are highly susceptible to DSS 
colitis (Rakoff-Nahoum et al., 2004). TLR4-deficient mice have decreased 
proliferation following DSS injury than wild-type mice. TLR4 expression is 
reduced in the IEC and LPMCs in IBD (Abreu, 2010). Activation through TLR4 
expression leads to increased TNFα production, as well as phagocytosis and 
translocation of bacteria. TLR2 and 4 are expressed at low levels by IECs in the 
normal colon and TLR3 in the small intestine and normal colon.  
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1.2 Inflammatory Bowel Disease 
Inflammatory bowel disease consists of 2 main conditions, Crohn’s disease (CD) 
and Ulcerative Colitis (UC), which are chronic relapsing and remitting diseases 
affecting 261,000 and 115,000 people in the UK respectively (NICE 2013). The 
aetiology is incompletely understood, but appears to be a complex combination 
of genetic and environmental interactions which result in immune dysfunction. 
Although there are similarities between UC and CD they are in fact different 
diseases. The challenge that they present is the increasing incidence worldwide 
(Molodecky et al., 2012) and the limitations of current treatments.  
UC and CD are both relatively recent diseases whose incidence has increased 
dramatically since the 1950s. Both are more common in Northern Europe and 
North America (Bernstein et al., 2006b) (Bernstein et al., 2006a) although the 
incidence is increasing in Asia (Thia et al., 2008) and Eastern Europe (Ng et al., 
2015) . It has also been traditionally more common in Caucasians, and genetic 
mutations in NOD 2, which are found in 15 % of CD individuals, are only found 
in Caucasians. However the incidence in Caucasians is also environmental, as 
the incidence in 2nd generation Asians in the UK is greater than resident 
Caucasians (Probert and Brown, 2008). The age of onset is different for UC and 
CD. UC develops throughout life whereas CD has two thirds of cases diagnosed 
in late adolescence and early adulthood. The age range of onset appears to be 
changing with increasing presentations in childhood as well as in elderly patients 
(Nguyen et al., 2017). There is a slight female preponderance in CD, which is 
not seen in UC. Smoking is a risk factor for CD (Calkins, 1989) as well as being 
associated with earlier recurrence following surgery and poorer response to 
 47 
medical treatment. Smoking in UC however, is protective (Ponder and Long, 
2013) .  Appendectomy before the age of 20 is also strongly protective against 
UC (Baron et al., 2005) 
1.2.1 Clinical and Histological Features of IBD 
The main symptoms of Crohn’s Disease are diarrhoea, abdominal pain and 
weight loss. Unexplained anaemia and growth failure in children may also be the 
only presenting features. The symptoms are often non-specific and chronic 
although acute abdominal pain raising the possibility of acute appendicitis can 
also be due to CD. Ulcerative colitis also presents with diarrhoea and abdominal 
pain, although bleeding per rectum is a more predominant feature than in CD, 
likely due to the different parts of the gut affected.  
Crohn’s Disease can affect any part of the intestine from the mouth to the anus, 
often discontinuously, although it more commonly affects the terminal ileum. 
Ulcerative colitis initially affects the rectum and can extend proximally to 
involve the whole colon. Both UC and CD are associated with extra intestinal 
features in up to 50% of patients. These include arthralgia, uveitis, pyoderma 
gangrenosum (Weizman et al., 2014) as well as other life-threatening conditions 
such as venous thrombo-embolism and primary sclerosing cholangitis. Extra 
intestinal manifestations are generally more common in active disease with the 
exception of ankylosing spondylitis and uveitis. CD is also associated with 
fistulas between loops of bowel or external and internal surfaces as well as 
abscesses (Yamamoto and Watanabe, 2014).  
Diagnosis is based on symptoms, examination, blood tests suggesting 
inflammation, and imaging. The gold standard is endoscopic and 
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histopathological evidence of inflammation. Biopsies favouring a diagnosis of 
CD show the presence of granulomas, show patchy lesions, a normal mucosal 
surface and predominantly involvement of the cecum and ileum (Feakins, 2014). 
In UC on the other hand, the inflammation and ulceration is limited to the 
mucosa, there is lymphocytic but a mainly granulocytic infiltration and crypt 
abscesses. There is a loss of goblet cells from the epithelium and extensive 
epithelial cell damage (DeRoche et al., 2014). Although CD and UC are 2 
separate diseases, the overlap in their presenting symptoms and areas of the 
bowel affected can make diagnosis difficult. In fact in some patients the 
diagnosis is changed (Prenzel and Uhlig, 2009). 
In CD, inflammation extends from the mucosa into the deeper muscle layers. In 
addition to inflammation, fibrosis is also seen in areas of previous inflammation 
and characterised by an excessive deposition of extracellular matrix proteins 
(Biancheri et al., 2015). Although the tissue can heal without the development of 
fibrosis, chronic inflammation and the repeated healing required appears to be 
associated with the development of fibrosis (Rieder et al., 2017). 
In UC the rectum is always affected and the disease can extend proximally to 
involve the whole of the colon. Twenty per cent of patients with UC have pan 




1.2.2 Management of IBD 
Management is both medical and surgical, although the need for surgery has 
reduced since the introduction of anti-TNF antibodies (Vogelaar et al., 2009). 
Treatment varies depending on the site and severity of disease and whether the 
treatment is to induce or maintain remission. The majority of drugs are used for 
both CD and UC although their indications vary slightly. Thus an accurate 
diagnosis is vital prior to treatment.  
Steroids are used in the acute phase in mild disease in CD in order to induce 
remission. Enteral therapy is used instead of steroids in children, however its 
efficacy in adults is limited, possibly due to poor compliance (Penagini et al., 
2016). In ulcerative colitis steroids may be required to induce remission in the 
acute phase. Mesalazines, either topically for left sided disease, or orally for 
more extensive disease, are the mainstay of treatment in UC. In both CD and UC 
more powerful immunosuppressants such as azathioprine, 6 mercaptopurine or 
less frequently methotrexate, are introduced if steroids or aminosalicylates are 
insufficient to induce remission, or if relapse occurs after cessation of steroid 
therapy (Timmer et al., 2016). 
In a proportion of patients with IBD in whom azathioprine is ineffective anti-
TNF treatments are possible. Those with clinical features of a poor prognosis 
such as severe endoscopic lesions, age less than 40 years, ileal or ileocolonic 
location and perianal disease at time of diagnosis, should be considered for anti-
TNF early (Jauregui-Amezaga et al., 2015). Anti-TNF treatment will be 
considered in a separate section.  
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Surgical intervention for CD is considered in individuals presenting with bowel 
obstruction, localised peritonitis thought to be due to appendicitis (Gomollón et 
al., 2017) (Yarur et al., 2014), and  in individuals with strictures amenable to 
surgery. Surgery plays an important role in the complications of CD such as 
strictures, fistulae and abscesses. There is no medical therapy shown to be 
effective in fibrosis, although endoscopic dilatation can be used if the strictures 
are short. Anti-TNF antibodies are used to help close fistulae and are effective in 
up to 60% of patients (Allocca et al., 2017) . 
In UC, fewer individuals have surgery than in CD, (Singh et al., 2015). This may 
however occur at first presentation with severe colitis, or in those patients in 
whom medical therapy is not an option. It is thought that surgical intervention is 
reducing with the use of biologics (Fu et al., 2014). 
1.2.3 Genetics of IBD 
The incidence of CD and UC is increased in first-degree relatives compared to 
the general population, and the incidence of CD particularly, is increased 
amongst monozygotic twins compared to dizygotic twins (38% concordance 
compared to 2% respectively); whereas in UC the concordance rates are 15% 
and 8% respectively (Halfvarson, 2011). However the absence of simple 
Mendelian inheritance suggests that multiple gene loci are responsible and that 
the pathophysiology is multifactorial. In 2001, Hugot et al., (2001) and Ogura et 
al., (2001) discovered that mutations in the gene encoding NOD (nucleotide 
oligomerization domain) 2, also known as caspase activation and recruitment 
domain (CARD) 15 was associated with CD in 15% of patients. NOD2 consists 
of two amino-terminal caspase recruitment domains (CARDs), a centrally 
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located domain, and multiple leucine-rich repeats (LRRs) at its carboxy-
terminal. Three different mutations were found in NOD2, all located near the 
leucine rich repeat (LRR) region (Hugot et al., 2001). Nucleotide 
oligomerization domain is expressed in gut epithelial cells, antigen presenting 
cells (macrophages and dendritic cells) and Paneth cells (Strober et al., 2014). 
NOD2 acts as an intracellular receptor for the peptidoglycan components of 
gram-positive bacteria and the mutations result in loss of function (van Heel et 
al., 2005). Activation leads to the activation of NFκB and mitogen-activated 
protein (MAP) kinase pathways and increases the production of pro-
inflammatory cytokines such as TNFα and IL-1β. The mutations are only found 
in Caucasians with CD and are associated with an increased incidence of ileal 
and fibrotic disease (Radford-Smith and Pandeya, 2006). Individuals 
homozygous for a single NOD2 mutation or compound heterozygotes have a 20-
40 fold increase in the risk of developing CD. However it is important to 
emphasise that many healthy individuals carry the same NOD2 mutations. 
NOD1, although structurally similar to NOD2 does not play a major role in 
disease susceptibility (Zouali et al., 2003). 
Since the advent of genome wide association studies, 163 different IBD loci 
containing gene variants either over-expressed or under expressed in IBD have 
been identified. The genes cluster into groups with different functions.  NOD2 
for example or the autophagy genes, ATG16L1 and IRGM relate to bacterial 
handling (Parkes et al., 2007). The IBD3 region (6p21.1-23) is an area that 
encompasses the human leukocyte antigen (HLA) genes and is associated with 
UC and CD (Muro et al., 2014). This region also encodes TNFα and the TNFα 
receptor. A polymorphism in the TNFα receptor was found to be associated with 
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infliximab response in Japanese patients (Matsukura et al., 2008). The 
Immunochip study led to the validation of a total of 163 genetic loci containing 
susceptibility to IBD (Jostins et al., 2012). IBD loci are shown in Table 1. 
Table 1.1 Inflammatory bowel disease (IBD) loci, represented by lead gene name, according to 
pathway. (Ek et al, 2014) 
1.2.4 The Microbiome in IBD  
There have been huge advances recently in the understanding of the relationship 
between the gut microbiome and IBD (especially CD) with the advent of next 
generation sequencing. Although the association between IBD and microbes has 
been suspected for many years due to clinical observations. Firstly the majority 
of lesions are seen in the areas of the bowel in which the microflora are most 
abundant, such as the terminal ileum and colon. The use of metronidazole, an 
antibiotic, is an effective treatment of peri-anal CD (Rutgeerts et al., 2004) 
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diverted, and lesions return when the faecal stream is reintroduced into the 
bowel (Flanagan et al., 2012), (Sauk et al., 2014). Bacteria, which are associated 
with the mucosa such as Bacteroides fragilis, have been found in increased 
numbers in the biofilm of IBD patients compared to controls (Swidsinski et al., 
2005). Dubinsky et al., (2006) showed that raised immune responses to 
microbial antigens were associated with a more aggressive phenotype in 
paediatric CD.  There is still controversy as to the pathogenesis of the microbiota 
and IBD. The proposed theories are discussed below. 
1.2.4.1 Functional changes in commensal bacteria 
Some strains of commensal bacteria are able to adhere to and invade intestinal 
epithelial cells such as a more virulent strain called AIEC (adherent/ invasive E. 
coli). AIEC showed the ability to survive and replicate within macrophages in 
ileal CD  (Baumgart et al., 2007) and increased numbers of E. coli are associated 
with reduced time before relapse  (Lopez-Siles et al., 2014) and active disease 
(Mylonaki et al., 2005). The receptor, which enables ileal colonisation in CD by 
AIEC, was identified by (Barnich et al., 2007) as CEACAM6. In addition its 
expression is activated by TNFα and IFNγ.  
1.2.4.2 Commensal Microbiota Dysbiosis 
The microbiome in IBD patients is less diverse than normal patients. Species 
which are reduced in IBD are clostridium species and Faecalibacterium 
praunitzii (Sokol et al., 2009), (Joossens et al., 2011). Low numbers of F 
prausnitzii are associated with post- resection relapse in CD, which is likely 
related to its purported ability to stimulate secretion of IL-10 by dendritic cells 
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(Wu et al., 2017). Nonetheless there are many who consider that the changes in 
the microbiota seen in IBD are secondary to inflammation, and that to imply that 
a dysbiosis is responsible for immune mediated diseases is far fetched. 
1.2.4.3 Defective containment of commensal bacteria 
NOD2, which is predominantly expressed in Paneth cells, senses muramyl 
dipeptide  (MDP) in the cytoplasm and triggers downstream signalling pathways 
such as NFκB thus initiating antimicrobial activities. NOD2/CARD15 
polymorphisms in CD prevent the effective binding of bacterial peptidoglycan 
and reduce the production of antimicrobial α-defensins and subsequent defective 
clearance of invasive bacteria  (Wehkamp et al., 2005).  
1.2.4.4 Defective host immunoregulation 
IBD patients have aggressive T cell responses to commensal bacteria and fail to 
develop tolerance to oral antigens (Sartor and Muehlbauer, 2007). The NOD2/ 
CARD15 mutation reduces effective clearance of bacteria. Finally IBD in IL-2 
null mice and IL-10 null mice depends on the presence of a normal gut flora. 
When the mice are placed in a germ-free environment they do not develop colitis 
but when they are exposed to either a single species of bacteria or a mixed 
bacterial colonisation they develop colitis very quickly (Podolsky, 1997). In 
2007 two autophagy related genes, immune-related GTPase family M protein 
(IRGM) and autophagy-related 16-like 1 (ATG16L1), were identified and 
associated with CD (Hampe et al., 2007), (Massey and Parkes, 2007). These are 
variants that control autophagy, the breakdown of bacteria by the 
autophagosome. Saitoh et al., (2008) showed that in mice knocked out for 
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ATG16L, a protein necessary for autophagic recruitment, TLR and TNF were 
stimulated leading to abnormal inflammasome activity in innate immune cells. 
 
1.2.5 Adaptive Immunity in IBD 
In CD there is an excessive Th1 response. CD4+ cells release large amounts of 
IFNγ, and TNFα, and Th1 inducing cytokines such as IL-12 and IL-18 are also 
increased. Rovedatti et al., (2009) showed that there is an increase in the number 
of Th17 and Th1/Th17 cells in IBD. In health, lamina propria T cells would 
normally undergo apoptosis in the absence of the peptides that activated them in 
PP, but in IBD, the presence of luminal peptides and survival cytokines such as 
IL-2, IL-7 and IL-15 allow the cells to persist and continue to secrete cytokines 
(MacDonald et al., 2011a). The large amounts of TNFα and IFNγ induce 
macrophages to fuse and become epithelioid giant cells and form granulomata. 
Resident myofibroblasts activated by pro-inflammatory cytokines produce 
matrix metalloproteinase (MMP)-3 that causes local mucosal damage and 
ulceration (Pender et al., 1997),  (Salmela et al., 2002). MMP3 is increased in 
the fistulous tracts of patients with CD (Scharl and Rogler, 2014) possibly due to 
increased IL-17A expression (Biancheri et al., 2013). The defective barrier 
allows microbes to infiltrate and exposes T cells and APC in the lamina propria 
to an increased amount of antigen that perpetuates the inflammatory cycle. 
Regulatory T cells have been shown to be vital in inhibiting inflammation in 
animal models of IBD and an inflammatory enteropathy similar to CD occurs 
following mutations in FOXP3 gene and results in no Tregs (Bennett et al., 
2001). 
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1.3 TNFα  and IBD 
The most important advance in IBD has been related to TNFα. Tumour Necrosis 
Factor α is a key cytokine in inflammation. It was initially found to be increased 
in the serum of children with an acute episode of UC and colonic CD (Murch et 
al., 1991). Following this TNFα secreting cells were increased in inflamed 
mucosa of CD and UC children (Breese et al., 1994). It was a step change in 
IBD therapy when (van Dullemen et al., 1995) showed that a single infusion of 
an anti-TNFα human/mouse chimeric monoclonal antibody (later called 
infliximab) led to the normalisation of the CDAI scores and mucosal healing in 8 
out of 10 Crohn’s patients. The clinical response to a single dose of infliximab 
was still evident 12 weeks after the infusion (Targan et al., 1997). Infliximab is 
effective in fistula healing (Yang et al., 2015). It was later shown to be effective 
in UC as well (Armuzzi et al., 2004). 
 
1.3.1 TNFα  production 
TNFα is produced mainly by macrophages but also by CD4+ T cells, NK cells, 
neutrophils and eosinophils. TNFα can regulate enterocyte growth and alter the 
permeability of the epithelial barrier (Feng et al., 2013). TNFα also stimulates 
the production of MMPs and other tissue remodelling enzymes in the intestinal 
mesenchymal cells that are central to regulating epithelial cell function (Salmela 
et al., 2002). 
Tumour Necrosis Factor alpha exists in two forms, initially as a trimer on the 
cell membrane called membrane TNFα, and after cleavage from the cell surface 
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by the matrix metalloproteinase TNFα converting enzyme (TACE/ ADAM17) 
into a secreted trimeric molecule, soluble TNFα (sTNFα) (Black et al., 1997). 
Soluble TNFα is produced by activated macrophages and lymphocytes and can 
bind to TNFRI and TNFRII. TNFRI and TNFRII are expressed on almost all 
nucleated cells. 
TACE also cleaves other transmembrane cytokines from the cell surface such as 
epidermal growth factor receptor ligands, TGFα, L-selectin, and IL-6 signalling 
pathways (Sharma et al., 2014). In addition, TACE deficient mice die at birth 
(Black et al., 1997). Mice with barely detectable levels of ADAM17 (due to 
generation of a new exon within the ADAM17 gene) show enhanced 
susceptibility in inflammatory bowel disease models as well as showing severe 
skin inflammation (Chalaris et al., 2010). The role of TACE in humans however 
may be less important as a TACE knockout patient has been described and leads 
a relatively normal life despite recurrent inflammation of the skin and bowel 
(Blaydon et al., 2011) . 
The natural inhibitor of TACE is TIMP-3, which also inhibits matrix 
metalloproteinases and has been shown to reduce pro-inflammatory cytokine 
transcripts in IBD biopsies (Monteleone et al., 2012). Virtually all cells in the 
body can express TACE, but it is barely detectable on the surface of most cells, 
suggesting that the expression of TACE on the cell surface is regulated. Erk-
mediated phosphorylation has been shown to translocate TACE to the cell 
surface (Soond et al., 2005) and iRhom2 is also needed for surface expression 
(Adrain et al., 2012).  
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Membrane TNFα is constitutively expressed on Natural Killer cells but not on 
resting T, B cells or monocytes (Caron et al., 1999) but is expressed on T cells, 
macrophages and monocytes following activation (Horiuchi et al., 2010). 
Membrane TNFα can bind to both receptors but generally has a greater affinity 
for TNFRII. Binding of TNFRI results in activation of the caspase dependent 
apoptosis, whereas the binding of TNFRII signals TRAF2 and NFκB induction, 
which has anti-apoptotic effects (Atreya et al., 2011). Both these effects occur 
locally due to the cell-to-cell interaction. In addition to acting as a ligand, 
mTNFα can also bring about changes in the cell expressing mTNFα via reverse 
signalling (Horiuchi et al., 2010). The cytoplasmic tail of the transmembrane 
TNFα protein can trigger intracellular signals such as activating MAP kinase 
increasing TGFβ production (Pallai et al., 2016). 
TNFα and particularly mTNFα play a major role in defending the host against 
bacterial, viral and parasitic infections. Various studies using transgenic mice 
expressing only mTNFα have shown the involvement of TNFα in macrophage 
migration and granuloma formation following Mycobacterium tuberculosis 
infection.  Membrane TNFα was shown to be sufficient to allow cell-cell 
signalling and control of mycobacterial infection in TNF KO mice and mTNFα 
mice (Fremond, 2005). 
1.3.2 Anti-TNFα  Agents 
Infliximab is a human/mouse chimeric monoclonal antibody, which is effective 
in UC and CD.  Other TNFα antibodies have been developed which differ in 
their structure. Adalimumab is a recombinant whole antibody and certolizumab 
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pegol is a PEGylated Fab’ fragment of a humanised monoclonal antibody that 
binds and neutralises human TNFα and both are effective in IBD (Nesbitt et al., 
2007). Etanercept is engineered from TNFRII coupled to the Fc receptor of IgG, 
and is not licensed for use in IBD due to its poor efficacy shown in a double 
blind trial (Sandborn et al., 2001). Although it is still not clear how anti-TNFα 
antibodies work in IBD it is helpful to consider their different structures to help 
understand their mechanisms of action. 
1.3.3 Proposed mechanisms of action of Anti-TNF Antibodies 
Originally TNFα was thought to be a key cytokine because when produced by 
macrophages it fed back and induced secretion of other inflammatory mediators 
such as IL-8 and diminished expression of adhesion molecules E-selectin and 
ICAM-1 (Feldman et al., 1998). Neutralising soluble TNFα in activated PBMC 
blocked this feedback loop. However this is clearly not the whole picture. The 
duration of the response to a single dose exceeds the half-life of the antibody. In 
addition, etanercept, which neutralises sTNFα is ineffective in the treatment of 
Crohn’s disease (Sandborn et al., 2001). Infliximab reduces the pro-
inflammatory cytokine IL-1β in PBMCs stimulated with LPS (Nesbitt et al., 
2007). Other pro-inflammatory cytokines such as IL-6 and IL-8 are reduced in 
the serum of CD patients following treatment with infliximab (Suzuki et al., 
2015).  
Complement-dependent cytotoxicity (CDC) of Jurkat cells and CHO cells 
bearing mTNFα is seen with infliximab but not etanercept (Mitoma et al, 2008, 
Arora et al, 2009) possibly due to the lack of the CH1 domain, which contains 
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the C1q binding site in etanercept. However Kaymakcalan et al (2009) was 
unable to show CDC by infliximab in activated human PBMCs.  
Antibody-dependent cytotoxicity (ADCC) occurs when the Fc portion of IgG1 
binds to Fc receptors on NK cells resulting in granzyme B and perforin release 
and ultimately target cell lysis. ADCC was seen using an mTNFα expressing 
cell line incubated with infliximab but not etanercept (Arora et al., 2009), 
(Nesbitt et al., 2007). The concept of reverse signalling on binding to mTNF 
leading to apoptosis has also been shown.  
Apoptosis, also known as programmed cell death, is an important process in the 
regulation of the immune system. A balance of pro- and anti- apoptotic factors 
exist and these can be set in motion in 2 ways; via the intrinsic cell death 
pathway or the extrinsic pathway. P53 is a regulatory molecule found in the 
cytoplasm which detects cell stress and DNA damage. If this is detected, p53 
translocates to the nucleus to initiate transcription of pro-apoptotic factors. The 
extrinsic pathway can be activated via various means such as the death receptor 
ligand interacting with FAS, TNF and TNFR1 interaction.  
Lugering et al., (2001) were the first to show apoptosis of peripheral blood 
monocytes following infliximab infusions in patients with CD. Apoptosis was 
then shown to occur in T cells in the lamina propria 24 hours after infliximab 
infusion as well as in vitro using an activated Jurkat cell line cultured with 
infliximab (Ten Hove et al 2002). Van den Brande et al., (2003) compared 
infliximab and etanercept and showed that both neutralise TNFα, however only 
infliximab induced apoptosis. Increased apoptosis was also shown in mucosal 
biopsies 10 weeks following infliximab and was caspase dependent (Di Sabatino 
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et al., 2004). Waetzig et al., (2005) showed apoptosis occurs via reverse 
signalling through mTNFα.  
A final non-immunological explanation for the success of infliximab is that 
activated fibroblasts in IBD express mTNFα and infliximab binding induces 
inside out signalling and a large increase in their production of TIMP-1, the 
endogenous MMP inhibitor (Di Sabatino et al., 2007). 
Anti-TNFα antibodies have allowed patients with IBD to achieve more than just 
symptomatic relief. Infliximab has been shown to induce mucosal-healing, and 
reduced the number of hospitalisations and surgery (Rutgeerts et al., 2004). The 
ACT I and ACT II trials showed that infliximab was also effective in steroid 
refractory ulcerative colitis (Rutgeerts et al., 2005). However only 50% of 
patients respond to infliximab and those that do respond do not all continue to do 
so. In addition to this, the side effects of anti-TNFα antibodies, principally 





1. To establish whether pharmacological and endogenous TACE inhibitors 
reduce the production of sTNFα and whether other pro-inflammatory 
cytokines would or would not be affected.  
2. To elucidate which cells express mTNFα in PBMCs and LPMCs and 
whether pharmacological and endogenous TACE inhibitors increase 
mTNFα expression. 
3. To elucidate whether infliximab reduces pro-inflammatory cytokines or 
causes apoptosis and the role of mTNFα in these activities. 
4. To determine if the addition of TNFα neutralising agents to mucosal 
biopsies from patients with IBD ex vivo has any effect on RTKs. 
5. To establish whether the addition of infliximab to mucosal biopsies 






3 Regulation of Soluble Tumour Necrosis Factor Production by 
Tumour Necrosis Factor Alpha Converting Enzyme (TACE) 
Inhibitors 
3.1 Introduction 
Tumour Necrosis Factor α is a key cytokine in inflammation. It was initially 
found to be increased in the serum of children with an acute episode of UC and 
colonic CD (Murch et al., 1991).   Breese et al., then showed that TNFα 
secreting cells were increased in inflamed mucosa of CD and UC children 
(Breese et al., 1994). It was a step change in IBD therapy when Targan et al. 
(1997) showed that neutralising TNFα reduced inflammation in CD, and later in 
UC by (Armuzzi et al., 2004).  Since then various anti-TNFα antibodies have 
been developed and are the mainstay of treatment for steroid-dependent CD and 
UC.  
Tumour Necrosis Factor α is a unique cytokine because it exists as a trimer in 2 
forms. Firstly on the cell membrane (mTNFα) and as a secreted molecule known 
as soluble TNFα (sTNFα). Both forms have been shown to be responsible for 
driving inflammation (Perrier et al., 2013). Soluble TNFα preferentially binds to 
TNFα receptor I whereas mTNFα preferentially binds to TNFRII (Rauert et al., 
2010) . 
Soluble TNFα is formed when membrane TNFα is cleaved from the cell surface 
by the TNFα converting enzyme (TACE) (Black et al., 1997). Virtually all cells 
in the body can express TACE but it is barely detectable on the surface of most 
cells, suggesting that the expression of TACE on the cell surface is regulated. 
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Erk-mediated phosphorylation has been shown to translocate TACE to the cell 
surface (Soond et al., 2005) and iRhom2 is also needed for surface expression 
(Adrain et al., 2012).  
Tumour necrosis factor α converting enzyme also known as A Disintigrin and 
Metalloproteinase-17 (ADAM 17) is responsible for a wide range of 
physiological processes in addition to TNFα release. These include processing 
adhesion proteins (L-selectin (Le Gall et al., 2009) and ICAM-1), cytokine 
receptors (IL-6R (Chalaris et al., 2011) and TNFR) and epidermal growth factor- 
receptor ligand (Dey et al., 2010).  In addition, TACE deficient mice die at birth 
(Black et al., 1997). Mice with barely detectable levels of ADAM17 (due to 
generation of a new exon within the ADAM17 gene) show enhanced 
susceptibility to inflammatory bowel disease models as well as severe skin 
inflammation (Chalaris et al., 2010).  The role of TACE in humans however may 
be less important as a TACE knockout patient has been described and leads a 
relatively normal life despite recurrent inflammation of the skin and bowel 
(Blaydon et al., 2011) . 
The natural inhibitor of TACE is tissue inhibitor of metalloproteinase (TIMP)-3 
(Amour et al., 2000), (Black et al., 1997). TIMP-3 is constitutively expressed in 
the intestinal epithelial cells in normal and inflamed human gut (Fréour et al., 
2009). TIMP-3 deficiency is associated with increased hepatic inflammation and 
TIMP-3 knockout mice develop severe colitis when exposed to 2,3,4 trinitri-
benzene-sulfonic acid (TNBS) compared to TIMP-3 transgenic mice which are 
resistant to TNBS colitis (Monteleone et al., 2012). TACE inhibition has been 
shown to increase TNFα mediated hyper permeability of the intestinal barrier 
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(Fréour et al., 2009).  In IBD (Monteleone et al., 2012) showed that TIMP-3 is 
down regulated in inflamed CD but up regulated when Smad7 (an inhibitor of 
TGF-β1 signalling) was knocked down.  (Cesaro et al., 2009) found that 
increased TACE expression in mucosal biopsies was associated with 
inflammation in CD and TIMP-3 expression was reduced. 
There has been an interest in the therapeutic benefits of TACE inhibitors to 
reduce TNFα production. Animal models have shown improved inflammation in 
arthritis and an iatrogenic inhibitor of TACE, compound 11p, was also shown to 
result in an improvement in inflammation in DSS induced colitis (Sharma et al., 
2014). However the role of TACE inhibitors in IBD is still unclear. 
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3.2 Aims 
To elucidate whether sTNFα production by LPMCs, PBMCs and biopsies would 
decrease with the addition of TACE inhibitors and whether other pro-
inflammatory cytokines would or would not be affected. Accordingly the 
following experiments were carried out.  
1. Soluble TNFα production was measured by activated PBMCs and 
LPMCs with the TACE inhibitor Marimastat in healthy controls. 
2. Soluble TNFα production was measured in supernatants of IBD colonic 
biopsies incubated with the endogenous TACE inhibitor TIMP-3. 
3. IL-1β, IL-6 and IL-8 were measured in supernatants of IBD colonic 
biopsies incubated with the endogenous TACE inhibitor TIMP-3.  
4. Soluble TNFα and other pro-inflammatory cytokine production was 
measured with a specific TACE inhibitor in activated PBMCs, and in the 
supernatants of biopsies cultured overnight. 
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3.3 Materials and Methods 
3.3.1 Patients and Sample Selection 
Colonic samples were taken from patients undergoing colonoscopy or colonic 
resections after obtaining consent. Specimens from intestinal resections were 
obtained from CD and UC patients requiring surgery or healthy control 
specimens of patients without CD or UC requiring surgery for cancer. Colonic 
biopsies were also taken from patients with diarrhoea without any endoscopic 
macroscopic inflammation who had functional diarrhoea at the end of their 
diagnostic work-up. Inflamed mucosal samples were from patients with active 
symptoms from their IBD and macroscopic evidence of inflammation. Patients 
were consented to take part in research which had been approved by the City and 
East London research ethics committee (10/H0704/74). 
3.3.2 Isolation of Peripheral Blood Mononuclear Cell (PBMC) 
Healthy individuals and patients with a confirmed diagnosis of CD or UC gave 
their consent to donate blood for the study. The blood was collected in 
heparinised tubes and then diluted with phosphate buffered saline (PBS 
Invitrogen, Paisley, UK) in a 1:1 ratio and layered onto an equal volume of 
Ficoll (Amersham Pharmacia Biotech, Little Chalfont, UK) for centrifugation at 
150g for 20 minutes at 21°C. The mononuclear cell layer was removed and 
washed with PBS and centrifuged again at 150g for 5 minutes at 10°C. The cell 
pellet was isolated and then resuspended. The cells were counted using a 
haemocytometer with trypan blue to measure cell viability.   
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3.3.3 Isolation of Lamina Propria Mononuclear Cells (LPMC) from 
Surgical Resections 
Specimens from intestinal resections were obtained following consent of CD and 
UC patients requiring surgery. Control specimens were obtained following 
consent of patients without CD or UC requiring surgery for cancer. The 
specimens were taken immediately to the histopathology department for 
macroscopic examination. Full thickness pieces of gut in length from 3-7cm 
were then removed from the specimen by the histopathologist and placed in 
ready to use Roswell Park Memorial Institute-1640 medium (RPMI)(Invitrogen) 
on ice and transported to the lab. The mucosa was removed from the specimens 
with scissors and incubated in calcium- and magnesium-free Hank’s balanced 
salt solution (HBSS) with 1mM ethylene tetra-acetic acid (EDTA)(Sigma-
Aldrich, Gillingham, Dorset, UK) for 30 minutes at 37°C with agitation in order 
to remove the mucus and epithelial cells. The tissue was then cut into 3-4mm 
pieces with a scalpel and digested in 1mg/ml collagenase (Sigma-Aldrich, 
Gillingham, UK) and DNAase I (10U/ml; Roche, Mannheim, Germany) with 
agitation for 60 minutes at 37°C. The suspension was then passed through a 
100µm cell strainer and washed in RPMI (Sigma-Aldrich, Gillingham, UK). The 
pellet was resuspended in 20ml of PBS and the LPMCs purified using Ficoll 
density gradient (centrifuged at 150g for 30 minutes at 20°C). The cell pellet 
was resuspended in RPMI and the cells counted using trypan blue. 
3.3.4 PBMC cell activation 
Following PBMC isolation, PBMCs were activated using LPS (Sigma-Aldrich, 
Pool, UK), anti CD3/ anti CD28 antibody or PMA/ Ionomycin. One millilitre 
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medium containing 1 million PBMCs was placed in a well of a 24 well plate in 
the following conditions; medium, LPS (100ng/ml; Sigma-Aldrich, Pool, UK), 
anti CD3/28 antibody (1µg/ml; eBioscience, San Diego, CA), LPS and 
Marimastat (10µM; Sigma-Aldrich, Pool, UK) and anti CD3/28 antibody and 
Marimastat (10µM) for 24 and 48 hours. A dose response experiment was later 
carried out with 0.1µM, 1µM and 10µM concentrations of Marimastat and LPS 
(100ng/ml; Sigma-Aldrich, Pool, UK). One millilitre of 1 million PBMCs were 
also placed in a 24 well plate in the following conditions; DMSO, PMA 
(50ng/ml Sigma-Aldrich, Pool, UK)/ Ionomycin (500ng/ml) for 4 hours, or PMA 
/ Ionomycin and GW280264X, a gift from Prof Stefan Rose-John (10µM). The 
supernatant was stored at -80°C for further analysis by ELISA. 
3.3.5 Organ Culture of Intestinal Mucosal Biopsies 
 Uninflamed and inflamed colonic biopsies obtained during colonoscopy were 
cultured (one biopsy per well) in 24 well plates (VWR International, 
Lutterworth, UK) in 300µl of serum free HL-1 medium (Cambrex BioScience, 
Wokingham, UK) for 24 and 48 hours at 37°C, 5% CO. TACE inhibitors 
(Marimastat 10µM, TIMP-3 100ng/ml (R and D Systems, Abingdon, UK) and 
GW280264X 10µM) were added. The supernatant was collected and stored at -
80°C and cytokines measured by ELISA. 
3.3.6 Measurement of Cytokine Production by ELISA  
Ninety-six well microplates (VWR International, Lutterworth, UK) were coated 
with anti-TNF-α (480µg/ml; R and D Systems, Abingdon, UK), anti-IL-6 
(360µg/ml; R and D Systems, Abingdon, UK), anti-IL-1β (480µg/ml; R and D 
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Systems, Abingdon, UK) or anti-IL-8 (720µg/ml; R and D Systems, Abingdon, 
UK) overnight at room temperature. The plates were then washed 3 times using 
ELISA wash solution (PBS 0.05% Tween (Sigma-Aldrich, Gillingham, UK)) 
and then blocked with PBS 0.1% bovine serum albumin (BSA) (TNFα, IL-6, IL-
1β) or PBS 0.01% BSA (IL-8) for 1 hour at 37°C. Following another 3 washes, 
the plates were incubated with serially diluted recombinant cytokine standards 
and diluted samples (1:2 for TNFα, 1:10 for IL-6, 1:5 for IL-1β, 1:50 for IL-8). 
After 2 hours the plates were washed and then incubated with a biotinylated anti-
TNF-α (4g/ml), anti-IL-6 (9µg/ml), anti-IL-1β (4µg/ml) and anti-IL-8 
(3.6µg/ml) for 1 hour. The plates were then washed and incubated with 
Streptavidin HRP (1 in 200) for 20 minutes before washing, and substrate 
solution was added. Finally without washing, 50µl of stop solution (H2SO4) was 
added in order to measure the optical density of each well using a microplate 




3.4.1 Soluble TNFα  production is reduced by Marimastat in both 
activated PBMCs and LPMCs 
Soluble TNFα levels were undetectable in non-activated PBMCs of healthy 
controls as expected. Soluble TNFα increased when PBMCs were activated with 
LPS to 1574pg/ml and 2422pg/ml in the 2 healthy donors after 24 hours. This 
increase is greater in one individual when PBMCs are incubated for 48 hours 
(2949pg/ml) but less in the other individual (901pg/ml). When Marimastat, was 
co-incubated with LPS for 24 or 48 hours the concentration of sTNFα was 
markedly reduced (Figure 4.1).  
Soluble TNFα also increased when PBMCs were activated with anti CD3/anti 
CD28 antibody for 24 hours (977.30pg/ml and 3975.30pg/ml) (Figure 3.1). 
Soluble TNFα is further increased when the PBMCs are activated for 48 hours 
(2696.50pg/ml and 10477.80pg/ml respectively). Marimastat again markedly 
reduced sTNFα production (Figure 3.1). 
3.4.2 The concentration of sTNFα  is reduced in a dose dependent manner 
by Marimastat 
PBMCs from one healthy individual were activated with either LPS or anti 
CD3/28 antibody and then increasing doses of Marimastat (0.1µM, 1µM and 
10µM) were added. Inhibition of sTNFα was in a dose dependent manner. 
Inhibition was much less in activated T cells than LPS activated monocytes 
(Figure 3.2). 
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Similar findings were seen when LPMCs were activated with anti CD3/28 and 
co-incubated with Marimastat (Figure 3.3). LPS was not used to activate LPMCs 
because it is well known that resident macrophages in normal colon are 
refractory to LPS (Nakata et al., 2006). Very little sTNFα is detected in LPMCs 
from normal colonic mucosa; a mean of 32.58pg/ml (with a range between 0 and 
124 pg/ml). Activation with anti-CD3/28 increases sTNFα to a mean of 1389.48 
(range between 174.60 pg/ml and 2724.60 pg/ml). Co-incubation with 
Marimastat reduced sTNFα to a mean of 573.18 (range between 365.50 pg/ml 
and 1224.60 pg/ml).  
3.4.3 Tissue Inhibitor of Metalloproteinase (TIMP)-3 significantly reduces 
sTNFα  in IBD biopsies. 
The natural inhibitor of TACE is TIMP-3, which also inhibits MMPs and has 
been shown to reduce pro-inflammatory cytokines expressed on CD LPMCs, as 
well as cytokine RNA in CD biopsies treated with recombinant TIMP-3 
(Monteleone et al., 2012). Further experiments were carried out adding TIMP-3 
to mucosal biopsies from four CD and three UC patients with active disease 
(Figures 3.4). There was a statistically significant (P=0.0241) reduction in 
sTNFα concentration in the supernatant of inflamed mucosal biopsies incubated 
with TIMP-3 when a paired t test was used. The reduction seen in CD biopsies 
alone was also significant (P=0.0437). The UC biopsies reduced from a mean of 
120.52 pg/ml in HL-1 to 49.30 pg/ml. 
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3.4.4 Tissue Inhibitor of Metalloproteinase (TIMP)-3 did not reduce IL-
1β , IL-8 or IL-6 in IBD biopsies.  
The pro-inflammatory cytokines IL-6, IL-1β and IL-8 in the supernatant of 
cultured biopsies from UC and CD patients were then determined using ELISA 
(Figure 3.4). There was a small reduction in IBD biopsies in the mean IL-1β, IL-
8 and IL-6 concentration. IL-1β reduced from 244 pg/ml (range of 0 to 845) in 
medium to 92.70 pg/ml (range of 18.12 to 403) with TIMP-3; IL-8 reduced from 
44709.38 pg/ml (range of 35886 to 48266) to 35,985.33 pg/ml (range of 75 to 
58826), and IL-6 reduced from 9899.54 pg/ml (range 1787.41 to 35,886) to 
7,029.43 pg/ml (range of 624.44 to 19976). 
3.4.5 The highly specific TACE inhibitor GW280264X reduces sTNFα  in 
activated PBMCs. 
We next tested a highly specific ADAM17 inhibitor, GW280264X, a gift from 
Prof Stefan Rose-John. PBMCs from healthy controls were activated with 
PMA/Ionomycin (Figure 3.5).  There was a significant increase in sTNFα with 
activation (p=0.012) and in addition co-incubation with the selective TACE 
inhibitor, significantly reduced secretion of TNFα  (p=0.019). 
Lamina propria mononuclear cells isolated from surgical resections of one UC 
and one CD individual were activated with anti CD3/28 antibody. There was an 
increase in sTNFα (1964.22 pg/ml from 97.56 pg/ml in the individual with CD 
and 1515.33 pg/ml from 159.78 pg/ml in the UC individual) (Figure 3.6).  
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3.4.6 The highly specific TACE inhibitor GW280264X significantly 
reduces sTNFα  in IBD.  
There was a statistically significant reduction in sTNFα (P=0.0033) in IBD 
biopsies (six UC patients and four CD patients). When a paired t test was applied 
to the UC biopsies alone there was also a significant reduction in sTNFα 
(P=0.037); sTNFα reduced from a mean of 221.05 pg/ml (a range of 156.27 to 
320.93) to a mean of 109.74 pg/ml (range of 25.1 to 220.9). A reduction was 
also seen ex vivo in inflamed CD biopsies from a mean sTNFα concentration of 
145.77 pg/ml (128.18 to 157.56) to a mean of 101.52 pg/ml (range of 56.44 to 
134.55) with 10µM GW280264X. The reduction however was not statistically 
significant. 








Figure 3-1  Soluble TNFα  increases with activation by LPS and anti CD3/28 and reduces with 
Marimastat 10µM. PBMCs from 2 control donors were incubated for 24 or 48 hours with medium, 
anti CD3/28 antibody or anti-CD3/28 antibody with 10µM Marimastat or LPS with or without 
Marimastat. There was an increase in sTNFα  with activation of both LPS and anti CD3/28 antibody, 




































































































































Figure 3-2 Soluble TNFα increases with activation by LPS and anti CD3/28 and reduced with 
Marimastat 10µM in a dose dependent manner. PBMCs from one healthy donor was incubated for 
24 or 48 hours with medium, anti CD3/28 antibody or anti-CD3/28 antibody with 0.1µM, 1µM and 
10µM Marimastat or LPS with or without 0.1µM, 1µM and 10µM Marimastat. There was an 
increase in sTNFα  in the supernatant with activation of both LPS and anti CD3/28 antibody which 


































































































































































































Figure 3-3  Soluble TNFα  increased in LPMCs isolated from four healthy individuals following 































sTNFα in Normal LPMCs in 24hrs 
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Figure 3-4 TIMP-3 significantly reduces sTNFα  in IBD biopsies. Biopsies from 4 CD and 3 UC 
patients were incubated in HL-1 medium with or without TIMP-3 (100ng/ml) for 24 hours. The 





































































































Figure 3-5. Soluble TNFα  significantly decreases with co-incubation of GW280264X. Peripheral 
blood mononuclear cells were incubated for 4 hours in DMSO, PMA/Ionomycin and PMA/I and 






























Figure 3-6.  The TACE inhibitor GW280264X reduces sTNFα  in activated IBD LPMCs of incubated 
for 24 hours. LPMCs were incubated with DMSO, anti CD3/28 antibody (1µ l/ml) and anti CD3/28 
antibody and GW280264X in one CD individual and one UC individual. The sTNFα  concentration 






































Figure 3-7 The TACE inhibitor GW280264X significantly reduces sTNFα  in IBD biopsies. Inflamed 
biopsies from 6 UC patients and 4 CD patients were incubated in HL-1 medium or GW280264X 
(10µM) for 24 hours. The concentration of sTNFα , IL-1β , IL-6 and IL-8 in the supernatant was 















































































I aimed to establish whether pharmacological and endogenous TACE inhibitors 
reduce soluble TNFα and identify any changes in other pro-inflammatory 
cytokines. Preliminary studies with a broad spectrum MMP inhibitor, 
Marimastat (Tsuji et al., 2002), showed a reduction in sTNFα secretion with 
10µM Marimastat. In fact a dose of 0.1µM was sufficient to reduce sTNFα 
production (Figure 3.2). Although Marimastat has not been tested in the gut 
previously, Tsuji et al showed that LPS-induced sTNFα in the plasma was 
reduced in mice following oral administration of Marimastat (Tsuji et al., 2002). 
The naturally occurring TACE inhibitor, TIMP 3 was then examined ex vivo. 
Consistent with the findings of Marimastat, a significant reduction in sTNFα 
was seen in the supernatant of organ culture medium following 24 hours 
incubation with TIMP-3. Previous studies have looked at endogenous TIMP-3 
expression in IBD, finding that its expression is reduced in active CD (Cesaro et 
al., 2009), but upregulated in quiescent CD and reduced in DSS induced colitis 
in mice (Sharma et al., 2014). Monteleone et al. (2012) and Sharma et al. (2014) 
found similar effects on sTNFα following the administration of TIMP-3 or 
compound 11p, a pharmacological TACE inhibitor.  
However their findings differ in the changes seen with other pro-inflammatory 
cytokines. Both studies showed a reduction in pro-inflammatory cytokines. The 
variation in these results could possibly be due to the patchy nature of 
inflammation in CD and greater numbers of samples are required to minimise 
this variability. It could also be due to the different experiments used. 
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(Monteleone et al., 2012) measured pro-inflammatory cytokines by post 
translational transcripts. Tumour necrosis factor is a master cytokine, which 
results in downstream release of pro-inflammatory cytokines; it is possible 
therefore that 24 hours is too short a time period to detect these changes. 
Carrying out an ELISA following 48 hours incubation may reveal a reduction in 
cytokines. Sharma et al., (2014) used a specific TACE inhibitor as opposed to 
TIMP-3 and experiments were in mice not human gut. Monteleone et al., (2012) 
showed the reduction in pro-inflammatory cytokines using flow cytometry of 
cell expression on LPMCs which again is likely to show changes earlier than in 
the supernatant. The concentration of TIMP-3 used was the same as Monteleone 
et al., (2012) (100ng/ml) but it may be helpful to use higher concentrations to 
see if the results are different.The reduction in sTNFα was not significant in UC, 
although the numbers are small. 
A specific TACE inhibitor was given by Professor Rose-John and tested in 
similar experiments to see if changes found were consistent and significant. The 
reduction in sTNFα in PBMCs was significant with GW280264X. The 
activation with PMA/ Ionomycin did not result in sTNFα concentrations 
comparable to activation with LPS or anti CD3/28 however. The changes seen 
ex vivo with GW280264X were similar to TIMP-3, showing a reduction in 
sTNFα. Interestingly the reduction was significant in UC biopsies but not CD 
biopsies (the opposite finding to TIMP-3). This again may be due to the patchy 
nature of inflammation. They may also suggest a difference in TACE inhibition 
between UC and CD individuals. 
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It is not clear from these results whether the reduction in sTNFα is anti-
inflammatory or pro-inflammatory. Fréour et al., (2009) showed increased 
intestinal permeability with TIMP-3 and postulated that this was due to the 
associated reduction in TNFR shedding. These results support previous findings 
that TACE inhibitors reduce sTNFα. 
Having examined the effects of TACE inhibitors on sTNFα and other pro-
inflammatory cytokines, the next step was to elucidate whether TACE inhibitors 
induce a reciprocal change in mTNFα expression. 
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4 Regulation of Membrane Tumour Necrosis Factor Alpha by 
Tumour Necrosis Factor Alpha Converting Enzyme 
Inhibitors 
4.1 Introduction 
Tumour necrosis Factor α is a key cytokine, which drives disease inflammation 
in inflammatory bowel disease. It is initially expressed on the cell surface as a 
trimer on the cell membrane. Membrane TNFα is constitutively expressed on 
Natural Killer cells but not on resting T, B cells or monocytes (Caron et al., 
1999), but is expressed on T cells, macrophages and monocytes following 
activation (Horiuchi et al., 2010). 
Membrane TNFα binds to TNFRI but has a greater affinity for TNFRII. Binding 
of TNFRI results in activation of caspase dependent apoptosis, whereas the 
binding of TNFRII signals TRAF2 and NFKappaB induction, which has anti-
apoptotic effects (Atreya et al., 2011). Both these effects occur locally due to the 
cell-to-cell interaction. In addition to acting as a ligand, mTNFα can also bring 
about changes in the cell expressing mTNFα via reverse signalling (Horiuchi et 
al., 2010). The cytoplasmic tail of the transmembrane TNFα protein can trigger 
intracellular signals such as activating MAPkinase increasing TGFβ production 
(Pallai et al., 2016). 
The importance of mTNFα is crucial to resolve colonic inflammation induced in 
immunodeficient mice (Perrier et al., 2013) . This was shown by comparing the 
improvement in colitis between mice treated with XENP1595, which neutralises 
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sTNFα alone, a monoclonal anti-TNFα antibody that neutralises both mTNFα 
and sTNFα and an isotype.  Improvement was only seen when mTNFα was 
neutralised. The role of mTNFα in IBD is also supported by the different 
efficacies of two anti-TNFα antibodies. Infliximab a monoclonal anti-TNFα 
antibody is effective in IBD, whereas etanercept is not (Sandborn et al., 2001). 
Both anti-TNFα antibodies neutralise sTNFα with similar binding, but 
etanercept binds weakly to mTNFα (Nesbitt et al., 2007) and (Vos et al., 2011). 
(Atreya and Neurath, 2016) also showed that response to infliximab was better 
in patients with an increased number of mTNFα cells in the mucosa.   
The 26 kilodalton (kd) mTNFα is cleaved into a 17kd fragment from the cell 
surface by the adamalysin TNFα Converting Enzyme (TACE) (Black et al., 
1997). Cesaro et al., (2009) showed that TACE mRNA is strongly expressed in 
biopsies from CD patients, but TIMP-3 the natural inhibitor of TACE is poorly 
expressed. Increased TACE expression at mRNA level was also shown in DSS 
induced colitis by Sharma et al., (2014),  which was associated with a 
suppression in TIMP-3. Treatment with compound 11p, a selective TACE 
inhibitor, ameliorated the colitis and restored pro-inflammatory cytokines to 
normal levels.  
Monteleone et al., (2012) showed mTNFα expression significantly increased on 
CD LPMCs when incubated with TIMP-3 for 36 hours and significantly reduced 




To elucidate which cells express mTNFα in PBMCs and LPMCs and whether 
TACE inhibitors increase mTNFα expression the following experiments were 
carried out. 
1. PBMCs were activated with LPS, anti-CD3/28 antibody and PMA/ 
Ionomycin and analysed using flow cytometry for mTNFα expression. 
2. Activated PBMCs and LPMCs were incubated with different TACE 
inhibitors and the change in mTNFα expression measured by flow 
cytometry. 
3. LPMCs from UC and CD patients were incubated with TACE inhibitors 
and the change in mTNFα expression measured by flow cytometry.!!
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4.3 Materials and Methods 
4.3.1 Isolation of Peripheral Blood Mononuclear Cell (PBMC) 
Healthy individuals and patients with a confirmed diagnosis of CD or UC gave 
their consent to donate blood for the study. The blood was collected in 
heparinised tubes and then washed with phosphate buffered saline (PBS 
Invitrogen, Paisley, UK) in a 1:1 ratio and layered onto an equal volume of 
Ficoll (Amersham Pharmacia Biotech, Little Chalfont, UK) for centrifugation at 
150g for 20 minutes at 21°C. The mononuclear cell layer was removed and 
washed with PBS and centrifuged again at 150g for 5 minutes at 10°C. The cell 
pellet was isolated and then resuspended. The cells were counted using a 
haemocytometer with trypan blue to measure cell viability.   
4.3.2 Isolation of Lamina Propria Mononuclear Cells (LPMC) from 
Surgical Resections 
Specimens from intestinal resections were obtained following consent of CD and 
UC patients requiring surgery. Control specimens were obtained following 
consent of patients without CD or UC requiring surgery for cancer. The 
specimens were taken immediately to the histopathology department for 
macroscopic examination. Full mural thickness sections varying in length from 
3-7cm were then removed from the specimen by the histopathologist and placed 
in ready to use Roswell Park Memorial Institute-1640 medium 
(RPMI)(Invitrogen) on ice and transported to the lab. The mucosa was removed 
from the specimens with scissors and incubated in calcium- and magnesium-free 
Hank’s balanced salt solution (HBSS) (Life Technologies, Paisley, UK) with 
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1mM ethylene tetra-acetic acid (EDTA)(Sigma-Aldrich, Gillingham, UK) for 30 
minutes at 37°C with agitation in order to remove the mucus and epithelial cells. 
The tissue was then cut into 3-4mm pieces with a scalpel and incubated in 
1mg/ml collagenase (Sigma-Aldrich, Gillingham, UK) and DNAase I (10U/ml; 
Roche, Mannheim, Germany) with agitation for 60 minutes at 37°C to break 
down intercellular connective tissues. The suspension was then passed through a 
100µm cell strainer and washed in RPMI (Sigma-Aldrich, Gillingham, UK). The 
pellet was resuspended in 20ml of PBS (Invitrogen, Paisley, UK) and the 
LPMCs purified using Ficoll density gradient (centrifuged at 150g for 30 
minutes at 20°C. The cell pellet was resuspended in RPMI and the cells counted 
using trypan blue. 
4.3.3 Separation of CD14+ and CD14- cells by magnetic beads. 
MACS (Miltenyi Biotec, Bergisch Gladbach, Germany) was also used to 
separate CD14+ and CD14- PBMCs which could then be activated with LPS or 
anti CD3/28 antibody respectively. The MACS separator uses magnetically 
labeled microbeads with CD14+ antibody, which bind to CD14+ PBMCs. The 
cell suspension is loaded onto a MACS column, which is placed in a magnetic 
field. The CD14+ cells are retained in the column, whilst the CD14- cells pass 
through and collected. When the magnetic field is removed from the column the 
CD14+ cells also pass through and can be collected separately.  Following 
PBMC isolation, PBMCs were centrifuged at 300g for 10 minutes at 4 °C and 
resuspended in 80µl of PBS (Invitrogen, Paisley, UK) per 107 cells. Cells were 
passed through a strainer to remove clumps and 20µl of CD14+ microbeads 
added. Cells were agitated and then refrigerated for 10 mins. Cells were then 
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washed in PBS (Invitrogen, Paisley, UK) and resuspended in up to 500µl of PBS 
before being passed through the MACS separator. 
4.3.4 PBMC and LPMC cell activation 
Following PBMC and LPMC isolation, 1 million PBMCs or LPMCs were 
activated using LPS (Sigma-Aldrich, Gillingham, UK), anti CD3/ anti CD28 
antibody (eBioscience, San Diego, CA) or PMA/ Ionomycin (Sigma-Aldrich, 
Gillingham, UK). One millilitre of 1 million PBMCs were placed in a well of a 
24 well plate in the following conditions; medium, LPS (100ng/ml; Sigma-
Aldrich, Gillingham, UK), anti CD3/28 antibody (1µg/ml; eBioscience, 
SanDiego, CA), LPS and Marimastat (10µM) and anti CD3/28 antibody and 
Marimastat (10µM) for 24 and 48 hours. One millilitre of 1 million PBMCs 
were also placed in a 24 well plate in the following conditions; DMSO, PMA 
(50ng/ml; Sigma-Aldrich, Gillingham, UK)/ Ionomycin (500ng/ml) for 4 hours, 
or PMA / Ionomycin and GW280264X, a gift from Prof Stefan Rose-John 
(10µM). After 4 hours the supernatant was stored at -80°C for analysis by 
ELISA whilst the cells were washed and prepared for FACS analysis. 
4.3.5 Staining for Flow Cytometry 
LPMCs and PBMCs from each of the conditions following activation were 
washed in 1 ml of FACS buffer and resuspended in 100µl of FACS buffer (PBS 
+ 2mM EDTA + 2% BSA). Cells were then incubated on ice with 20µl of FACS 
blocking buffer (Human Fc Receptor Binding Inhibitor) (eBioscience; Hatfield, 
England) to reduce non-specific binding via Fc receptors. The cells were then 
incubated with FITC bound mTNFα antibody or its isotype control (R and D 
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systems, Abingdon, UK), PeCy7 bound TNFα antibody or its isotype control 
(BioLegend, London, UK), Pacific Blue anti-CD14 antibody (BD Bioscience, 
Oxford, UK) and PE anti-CD3 antibody (BioLegend, London, UK) for 20-30 
minutes at 37°C in the dark. Cells were then washed three times in FACS buffer 
and analysed using LSRII flow cytometry (BD Bioscience, Oxford, UK). Isotype 
controls were purchased from the same manufacturer as the antibodies. Data was 
analysed using FlowJo software (Tree Star Inc, OR, USA). 
4.3.6 Gating Strategy 
Lymphocytes were gated using forward scatter and side scatter properties. 
Doublets were then excluded using forward scatter and side scatter width. CD3+ 
or CD14+cells were then identified by PE and Pacific Blue fluorescence 
respectively. The FITC isotype and mTNF FITC fluorescence enabled the final 
gating to quantify mTNF+ CD3+ and mTNF+ CD14+ cells. 
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4.4 Results 
4.4.1 Membrane TNFα expression significantly increases in PBMCs 
activated with anti CD3/28 antibody 
PBMCs were activated with anti CD3/28 for 48 hours and analysed by flow 
cytometry. Initially an antibody for intracellular TNFα detection was used as the 
vendor claimed that it was also effective in detecting membrane TNFα. 
However another antibody specific for membrane TNFα was also purchased and 
compared to optimise the detection of mTNFα expression (Figure 4.1). There 
was a significant increase in mTNFα expression (P=0.019) with anti CD3/28 
activation using the membrane specific antibody (Figure 4.2). There was no 
difference in mTNFα expression on PBMCs incubated with medium by the two 
antibodies (a mean of 1.6 for iTNFα antibody and a mean of 0.8 for the mTNFα 
antibody), but there was an increased detection in mTNFα by the latter in 
PBMCs incubated with anti-CD3/ anti-CD28 antibody (mean of 3.6 for iTNFα 
and a mean of 9.7 for mTNFα) (Figure 4.2).  
4.4.2 mTNFα  expression was greater with a PE bound CD3+ antibody 
than MACS separated CD14- cells. 
In order to measure the mTNFα expression in monocytes and T cells two 
different methods were carried out and then compared. PBMCs were separated 
into CD14+ and CD14- cells. The former were activated with LPS and mTNFα 
expression measured by FACS (Figure 4.3). CD14- cells were activated with 
anti CD3/ anti CD28 and mTNFα expression measured by FACS (Figure 4.4). 
The mTNFα expression was also measured in similar experiments in which 
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PBMCs were not separated but anti CD3 or antiCD14 antibodies used to 
quantify the cell populations. There was a higher detection of CD3+cells when a 
PE bound CD3+ antibody was used than when the CD14- cells separated by 
magnetic beads. There was no difference between the two methods in the 
detection of CD14+ mTNFα cells (Figure 4.5).  
4.4.3 Marimastat does not increase the mTNFα  expression on activated 
PBMCs. 
Membrane TNFα is significantly increased on PBMCs activated with anti 
CD3/28 antibody but the expression of mTNFα is not increased further with 
Marimastat. PBMCs do not show an increase in mTNFα with LPS activation or 
with LPS and Marimastat (Figure 4.6).  
 
4.4.4 Marimastat increases mTNFα  in UC but not in CD LPMCs.  
LPMCs from inflamed colon were incubated in medium or activated with anti 
CD3/28 antibody (1µg/ml) and Marimastat (10µM) and CD3+mTNFα cells 
calculated by FACS. In CD mTNFα increased with anti CD3/28 from 1.1% to 
20.4% but reduced with Marimastat to 1.45%. In UC mTNFα increased with 




4.4.5 The highly specific TACE inhibitor GW280264X significantly 
increases mTNFα  expression in CD3+ PBMCs.  
There was a statistically significant (P=0.01) increase in mTNFα expression 
between activated lymphocytes with GW280264X compared to no GW280264X 
in CD3+ PBMCs. The mean fluorescence intensity was also statistically 









Figure 4-1. PBMCs from healthy donors were incubated in medium or anti CD3/28 antibody for 48 
hours. The mTNFα  expression was measured by flow cytometry comparing two antibodies, one for 
TNFα  (intracellular or membrane) and the other specifically for membrane TNFα . The upper panel 
is the non specific antibody and mTNFα  detected was 1.08% of total cell count. The lower panel is 







Figure 4-2 . mTNFα  expression increased significantly when detected with mTNFα  antibody. 
PBMCs from 3 healthy donors activated with anti CD3/28 for 48 hours and stained with either non 
specific TNFα  (iTNFα) antibody or mTNFα  antibody for FACS analysis. Figure shows the mean and 
standard deviation of 3 experiments. The mTNFα  antibody detected an increased percentage of 






























Figure 4-3. PBMCs from healthy controls were separated into CD14+ and CD14-ve cells by magnetic 
beads. CD14+ve cells were incubated in medium or LPS (100ng/ml) for 24 hours and the cells 
analysed for mTNFα  expression by flow cytometry. Membrane TNFα  expression increased with LPS 
from 2.73% to 9.11% in the first experiment (upper panel) and 2.45 to 5.56% in the second 




Figure 4-4 . PBMCs from healthy controls were separated into CD14+ and CD14-ve cells by magnetic 
beads. CD14-ve cells were incubated in medium and anti CD3/28 antibody (1µg/ml) for 48 hours and 
the cells analysed for mTNF expression with flow cytometry. Membrane TNFα  expression increased 





Figure 4-5. CD3+PE staining detected more mTNFα  cells than MACS selection of CD14- cells. 
PBMCs were separated into CD14+ and CD14- populations and then stimulated before FACS 
analysis of mTNFα+ expression. In addition PBMCs were stimulated without prior MACS 
separation CD3+PE and CD14+Pacific Blue used to detect the different cell populations. The result 
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Figure 4-6. Membrane TNFα  is significantly increased with anti CD3/28 antibody. PBMCs were 
incubated in medium or activated with anti CD3/28 antibody (1µg/ml) or LPS (100ng/ml) and 
Marimastat (10µM) added. The FACS plot shows CD3+mTNFα  cells and CD14+mTNFα  cells 
calculated by FACS.  Marimastat does not increase mTNFα  following activation with anti CD3/28 or 
LPS. Graph showing the mean % of mTNFα  and the standard deviation where n=6 in CD3+ cells 























































Figure 4-7. Marimastat increases mTNFα  in UC but not in CD. Plots show one experiment with UC 
and one with CD. LPMCs from inflamed colon were incubated in medium or activated with anti 
CD3/28 antibody (1µg/ml) and Marimastat (10µM) and CD3+mTNFα  cells calculated by FACS. In 
CD mTNFα  increased with anti CD3/28 from 1.1 to 20.4% but reduced with Marimastat to 1.45%. 
In UC mTNFα  increased with activation from 2.72% to 11.1% and further increased with 








Figure 4-8. The highly specific TACE inhibitor GW280264X significantly increases mTNFα 
expression in CD3+ cells. A representative plot of PBMCs cultured in medium, P/I or P/I with 











Figure 4-9 The highly specific TACE inhibitor GW280264X significantly increases mTNFα  
expression in CD3+ cells. PBMCs were cultured in medium, P/I or P/I with GW280264X (10µM) for 
4 hours. There was a statistically significant (P=0.01) increase in mTNFα  expression between 
activated lymphocytes with GW280264X compared to no GW280264X in CD3+cells. The mean 









































































































The aim was to establish which cells express mTNFα and whether 
pharmacological TACE inhibitors increase the expression of mTNFα. 
Membrane TNFα expression was not detected in resting CD3+ or CD14+ 
control PBMCs or LPMCs. This is consistent with findings by Caron et al., 
(1999) in which resting T cells did not express mTNFα. The expression of 
mTNFα increased significantly in CD3+ PBMCs with anti CD3/28 antibody 
activation but not with P/I activation. Alternatively mTNFα expression was 
increased on CD14+ PBMCs with P/I activation but not LPS. It is known that 
LPS can cause a silencing of mTNFα through reverse signalling (Eissner et al., 
2000), it is possible that these differences are due to the small number. 
The first TACE inhibitor tested in this study was the broad spectrum MMP 
inhibitor Marimastat (Tsuji et al., 2002). There was no further increase in 
mTNFα expression following activation with Marimastat in PBMCs activated 
with LPS or anti CD3/28 antibody. Tsuji et al., (2002) show Marimastat reduces 
plasma sTNFα in mice in LPS induced sTNFα production, however mTNFα 
was not measured. In this study Marimastat increases mTNFα expression in one 
experiment with UC LPMCs. Similarly Monteleone et al., (2012) show mTNFα 
expression increases in CD LPMCs with the endogenous TACE inhibitor 
TIMP3. Membrane TNFα was measured by flow cytometry using infliximab to 
bind to mTNFα and a secondary antibody bound to a fluorochrome to detect 
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mTNFα.  Comparative experiments were not done in this study between the 
specific mTNFα antibody and infliximab.  
The selective TACE inhibitor GW280264X statistically increased mTNFα in 
CD3+ activated PBMCs. The differences in the results with the two TACE 
inhibitors tested are likely due to their selectivity. Marimastat was originally 
designed as a MMP-9 inhibitor but at the concentrations used in this study, the 
selectivity for TACE is poor. GW280264X alternatively is a highly selective 
TACE inhibitor as demonstrated by the significant increase in mTNFα 
expression found. 
Having shown how sTNFα and mTNFα expression change with stimulation and 
TACE inhibition, the next step was to elucidate possible mechanisms of action 




5 Functional Effects of Anti-Tumour Necrosis Factor Alpha 
Antibodies 
5.1 Introduction 
Anti-TNFα agents are used in patients with CD and UC who continue to have 
active disease despite being treated with steroids or azathioprine. Infliximab was 
the first anti-TNFα antibody to be licensed for use in CD and is effective in 
inducing remission in about half of patients with CD and about a third of 
patients with UC (Hanauer, 2002) (Rutgeerts et al., 2005). Other anti-TNF 
agents have since been developed, namely adalimumab, etanercept, certolizumab 
and golimumab, however etanercept which showed comparable efficacy to 
infliximab in patients with rheumatoid arthritis, is not licenced for use in CD due 
to less convincing efficacy (Sandborn et al., 2001).  
 
Hanauer (2002) showed that infliximab was more effective in maintaining 
remission when 8 weekly infusions are given rather than a single infusion, 
however a loss of response still occurs in up to one third of patients. The 
mechanism by which infliximab induces remission is not clear but proposed 
mechanisms have included neutralising TNFα and reducing the production of 
pro-inflammatory cytokines downstream, inducing direct or indirect apoptosis of 
T cells or macrophages bearing mTNFα, regulatory macrophages, and 
complement mediated lysis of these cells (Mizutani et al., 2013, ten Hove et al., 
2002a, Mitoma et al., 2008). Many studies have used the different efficacies of 
etanercept and infliximab to support whether the mechanism of action studied is 
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likely to play a significant role in IBD. These mechanisms are discussed in more 
detail below.  
 
Infliximab is a human/mouse chimeric monoclonal antibody and etanercept is 
engineered from TNFRII coupled to the Fc receptor of IgG. Originally TNFα 
was thought to be a key cytokine because when produced by macrophages it fed 
back and induced secretion of IL-1, IL-6, IL-8 and GM-CSF (Butler et al., 
1995). Neutralising soluble TNFα blocked this feedback loop (Butler et al, 
1995). Infliximab reduces the pro-inflammatory cytokine IL-1β in PBMCs 
stimulated with LPS (Nesbitt et al., 2007). Other pro-inflammatory cytokines 
such as IL-6 and IL-8 are reduced in the serum of CD patients following 
treatment with infliximab (Mizutani et al., 2013). 
  
Lügering et al., (2001) were the first to show apoptosis of peripheral blood 
monocytes following infliximab infusions in patients with CD. Apoptosis was 
then shown to occur in T cells in the lamina propria 24 hours after infliximab 
infusion as well as in vitro using an activated Jurkat cell line cultured with 
infliximab (ten Hove et al., 2002b). Van den Brande et al., (2003) compared 
infliximab and etanercept and showed that both neutralise TNFα, however only 
infliximab induced apoptosis. Increased apoptosis was also shown in mucosal 
biopsies 10 weeks following infliximab and was caspase dependent (Di Sabatino 
et al., 2004). Waetzig et al., (2005) showed apoptosis occurs via reverse 
signalling through mTNFα. 
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Complement-dependent cytotoxicity (CDC) of Jurkat cells and CHO cells 
bearing mTNFα is seen with infliximab but not etanercept (Mitoma et al., 2008, 
Arora et al., 2009) possibly due to the lack of the CH1 domain by etanercept. 
However Kaymakcalan et al., (2009) was unable to show CDC by infliximab in 
activated human PBMCs.  
 
Antibody-dependent cytotoxicity (ADCC) occurs when the Fc portion of IgG1 
binds to Fc receptors on NK cells resulting in granzyme B and perforin release 
and ultimately target cell lysis. ADCC was seen using an mTNFα expressing 
cell line incubated with infliximab but not etanercept (Arora et al., 2009). 
Nesbitt et al., (2007) however showed ADCC using infliximab and etanercept in 
a TNFα expressing cell line, although the level of ADCC seen with etanercept 
was much less than infliximab. Mitoma et al., (2008) however showed similar 
levels of ADCC with etanercept as with infliximab in a mTNFα expressing 
Jurkat cell line. It has also been suggested that infliximab binds to mTNFα but 
etanercept does not (Vos et al., 2011).  
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5.2 Aims 
To elucidate whether infliximab reduces pro-inflammatory cytokines, causes 
apoptosis and the role of mTNFα in these activities. Accordingly the following 
experiments were carried out 
1. Pro-inflammatory cytokines were measured by ELISA in the 
supernatants of inflamed IBD biopsies incubated with infliximab. 
2. Apoptosis was measured in an mTNFα expressing cell line incubated 
with IgG1 or infliximab. 
3. Apoptosis was measured in PBMCs and LPMCs activated with anti 
CD3/28 and infliximab in cells from healthy controls and IBD patients. 
This work was carried out in collaboration with Paolo Biancheri. 
4. Apoptosis was measured in PBMCs activated with PMA/ Ionomycin and 
co-incubated with the TACE inhibitor GW280264X (a gift from 
Professor Rose-John) before the addition of infliximab or IgG1. 
 
 110 
5.3 Materials and Methods 
5.3.1 Organ Culture of Intestinal Mucosal Biopsies 
 Uninflamed and inflamed colonic biopsies obtained during colonoscopy were 
cultured (one biopsy per well) in 24 well plates (VWR International, 
Lutterworth, UK) in 300µl of serum free HL-1 medium (Cambrex BioScience, 
Wokingham, UK) and infliximab (10µg/ml; Remicade; Schering-Plough, 
Welwyn Garden City, UK) and IgG1 (10µg/ml) for 24 hours at 37°C, 5% CO. 
The supernatant was collected and stored at -80°C and cytokines measured by 
ELISA. 
 
5.3.2 Measurement of Cytokine Production by ELISA  
Ninety-six well microplates (VWR International, Lutterworth, UK) were coated 
with anti-IL-6 (360µg/ml; R and D Systems, Abingdon, UK), anti-IL-1β 
(480µg/ml; R and D Systems, Abingdon, UK) or anti-IL-8 (720µg/ml; R and D 
Systems, Abingdon, UK) overnight at room temperature. The plates were then 
washed 3 times using ELISA wash solution (PBS 0.05% Tween (Sigma-Aldrich, 
Gillingham, UK)) and then blocked with PBS 0.1% bovine serum albumin 
(BSA) (IL-6, IL-1β) or PBS 0.01% BSA (IL-8) for 1 hour at 37°C. Following 
another 3 washes, the plates were incubated with serially diluted recombinant 
cytokine standards and diluted samples (1:10 for IL-6, 1:5 for IL-1β, 1:50 for IL-
8). After 2 hours the plates were washed and then incubated with a biotinylated 
anti-IL-6 (9µg/ml), anti-IL-1β (4µg/ml) and anti-IL-8 (3.6µg/ml) for 1 hour. The 
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plates were then washed and incubated with Streptavidin HRP (1 in 200) for 20 
minutes before washing and substrate solution was added. Finally without 
washing 50µl of stop solution (H2SO4) was added in order to measure the 
optical density of each well using a microplate reader at 450nm. 
5.3.3 Culture of Chinese Hamster Ovary (CHO) cell lines 
A CHO cell line transfected with membrane TNFα and a CHO cell line with an 
empty vector (VH2, Hinxton, Cambridge) were cultured in tissue culture flasks 
with F12 GIBCO Nutrient mixture with L Glutamine (Invitrogen, Paisley, UK) 
with 1% penicillin/ streptomycin, 10% FBS and 400µg/ml Hygromycin B added. 
Cells were passaged two or three times a week by removing the medium, rinsing 
the cell layer with sterile PBS and adding 3 mls Accutase (PAA Laboratories, 
Pasching, Austria) and placing in an incubator for 20 minutes. Ten ml of 
complete medium was then added to deactivate the Accutase (PAA Laboratories, 
Pasching, Austria) and 1/6 of the total volume of cells added to a new flask with 
fresh medium. The remaining cells were washed with PBS and centrifuged at 
150g for 5 minutes at 10°C and the cell pellet resuspended before cells were 
counted with trypan blue to measure cell viability.  
 
5.3.4 Isolation of Peripheral Blood Mononuclear Cell (PBMC) 
Healthy individuals and patients with a confirmed diagnosis of CD or UC gave 
their consent to donate blood for the study. The blood was collected in 
heparinised tubes and then washed with phosphate buffered saline (PBS 
Invitrogen, Paisley, UK) in a 1:1 ratio and layered onto an equal volume of 
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Ficoll (Amersham Pharmacia Biotech, Little Chalfont, UK) for centrifugation at 
150g for 20 minutes at 21°C. The mononuclear cell layer was removed and 
washed with PBS and centrifuged again at 150g for 5 minutes at 10°C. The cell 
pellet was isolated and then resuspended. The cells were counted using a 
haemocytometer with trypan blue to measure cell viability.   
 
5.3.5 Isolation of Lamina Propria Mononuclear Cells (LPMC) from 
Surgical Resections 
Specimens from intestinal resections were obtained following consent of CD and 
UC patients requiring surgery. Control specimens were obtained following 
consent of patients without CD or UC requiring surgery for cancer. The 
specimens were taken immediately to the histopathology department for 
macroscopic examination. Full thickness pieces of gut in length from 3-7cm 
were then removed from the specimen by the histopathologist and placed in 
ready to use Roswell Park Memorial Institute-1640 medium (RPMI)(Invitrogen, 
Paisley, UK) on ice and transported to the lab. The mucosa was removed from 
the specimens with scissors and incubated in calcium- and magnesium-free 
Hank’s balanced salt solution (HBSS) with 1mM ethylene tetra-acetic acid 
(EDTA)(Sigma-Aldrich, Gillingham, UK) for 30 minutes at 37°C with agitation 
in order to remove the mucus and epithelial cells. The tissue was then cut into 3-
4mm pieces with a scalpel and digested in 1mg/ml collagenase (Sigma-Aldrich, 
Gillingham, UK) and DNAase I (10U/ml; Roche, Mannheim, Germany) with 
agitation for 60 minutes at 37°C. The suspension was then passed through a 
100µm cell strainer and washed in RPMI (Sigma-Aldrich, Gillingham, UK). The 
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pellet was resuspended in 20ml of PBS and the LPMCs purified using Ficoll 
density gradient (centrifuged at 150g for 30 minutes at 20°C). The cell pellet 
was resuspended in RPMI and the cells counted using trypan blue. 
5.3.6 PBMC cell activation 
Following PBMC isolation, PBMCs were activated using anti CD3 / anti CD28 
antibody (eBioscience, SanDiego,CA) or PMA/ Ionomycin. One millilitre 
medium containing 1 million PBMCs was placed in a well of a 24 well plate in 
the following conditions; medium, anti CD3/28 antibody (1µg/ml; eBioscience, 
SanDiego, CA), anti CD3/28 antibody (1µg/ml) and infliximab (10µg/ml; 
Remicade, Scering-Plough, Welwyn Garden City, UK) and anti CD3/28 
antibody (1µg/ml) and IgG1 (10µg/ml) for 24 hours. One millilitre of 1 million 
PBMCs were also placed in a 24 well plate in the following conditions; PMA 
(50 ng/ml Sigma-Aldrich, Gillingham, UK)/ Ionomycin (500 ng/ml) for 4 hours, 
or PMA/ Ionomycin and GW280264X, a gift from Prof Stefan Rose-John 
(10µM) and either IgG1 (100µg/ml) or infliximab (100 µg/ml; Remicade, 
Schering-Plough, Welwyn Garden City, UK).  
 
5.3.7  Flow Cytometric detection of membrane TNFα    
CHO cells were aspirated and washed in 1 ml of FACS buffer and resuspended 
in 100µl FACS buffer (PBS, 2mM EDTA, 2% BSA). Cells were then incubated 
with 5µl fluorescin conjugated membrane TNF antibody (R and D, Abingdon, 
UK), or its matched isotype, for 20-30 minutes at 37°C in the dark. Cells were 
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then washed three times in ice-cold FACS buffer and analysed by flow 
cytometry using LSRII (BD Bioscience, Oxford, England). 
 
5.3.8 Measurement of Apoptosis using  Annexin V 
Annexins are a family of calcium dependent phospho-lipid binding proteins that 
preferentially bind phosphatidylserine (PS). PS is normally located on the inner 
layer of the plasma membrane, however when apoptosis is initiated, PS is 
translocated to the outer layer of the phospholipid bilayer marking cells for 
phagocytosis. Fluorescently labelled Annexin V binds to the PS on the cell 
surface. In the early stages of apoptosis viability dyes such as propidium iodide 
are excluded by the plasma membrane. Thus cells in early apoptosis are positive 
for Annexin V but negative for PI. Whereas cells in late apoptosis, in which the 
cell membrane has lost its integrity, stain positively for Annexin V and PI. 
PBMCs were washed once in PBS and then once with binding buffer. PBMCs 
were then resuspended in 250µl of binding buffer and 10µl of Annexin V 
(eBioscience, San Diego, CA) and incubated for 15 minutes at room 
temperature. Cells were then washed in binding buffer and resuspended in 200µl 
of binding buffer (eBioscience,San Diego, CA) and 5µl of PI (eBioscience, 
SanDiego, CA) added. Cells were put on ice in the dark until analysis by flow 
cytometry. Data was analysed using FlowJo software (Tree Star Inc, OR, USA). 
 115 
5.4 Results 
5.4.1 Infliximab and etanercept do not reduce the production of IL-1β , 
IL-6 or IL-8 in inflamed IBD biopsies cultured ex vivo.  
Inflamed biopsies from four CD and 1 UC patient were incubated for 24 hours 
with infliximab (10µg/ml), etanercept (10µg/ml) or IgG1 (10µg/ml). There was 
a wide range of IL-1β, IL-6 and IL-8 produced which did not change with the 
addition of infliximab or etanercept (Figure 5.1).  
5.4.2 Surface TNFα  on CHO cells 
CHO cells were cultured and passaged two to three times per week. At passage 
cells that were removed were washed and mTNFα expression measured using a 
FITC conjugated anti-mTNFα antibody (Figure 5.2). The mean from 3 
experiments was 74.3% (range of 55-91%) (Figure 5.3). There was no staining 
of control CHO cells. 
5.4.3 Apoptosis is not increased in the mTNFα  transfected CHO cell line 
cultured with infliximab.  
There was no difference in apoptosis in CHO cells incubated for 24 hours with 
infliximab (10µg/ml) compared to IgG1 (10µg/ml). Apoptosis was measured 
using Annexin V and PI (Figure 5.4). These results were similar in CHO cells, 




5.4.4 Apoptosis does not increase in CD14-ve PBMCs incubated with 
infliximab compared to IgG1 or etanercept.  
Figure 5.5 shows two experiments in which CD14-ve PBMCs activated with anti 
CD3/28 antibody for 48 hours are then incubated with IgG1 (10µg/ml), 
infliximab (10µg/ml) and etanercept (10µg/ml). Apoptosis with infliximab is 
greater in one experiment only but no different in the second experiment. 
5.4.5 Apoptosis in unstimulated CD3+LPMCs in inflamed CD was not 
increased.  
Figure 5.6 shows one experiment in which inflamed CD LPMCs were isolated 
and incubated with infliximab or IgG1 for 24 hours. There was no difference in 
apoptotic cells although this was only one experiment. 
5.4.5 The TACE inhibitor GW280264X does not increase the apoptosis in 
PBMCs incubated with infliximab.   
PBMCs from healthy controls were incubated for 48 hours with anti-CD3/ anti 
CD28 (1µg/ml) antibody with and without GW280264X (10µM). Infliximab 
(100µg/ml) or IgG1 (100µg/ml) was then added for 24 hours. A higher 
concentration was used as this was the concentration used by Nesbitt et al 
(2007). The cells were then stained with Annexin V and Propidium Iodide for 
apoptosis and analysed by flow cytometry. Greater apoptosis was detected with 
infliximab and GW280264X, however an increase in apoptosis was also detected 





Figure 5-1. Infliximab and etanercept did not reduce IL-1β , IL-6 or IL-8 in inflamed IBD biopsies. 
Inflamed biopsies from four CD and 1 UC patient were incubated for 24 hours with infliximab (10 
µg/ml), etanercept (10µg/ml) or IgG1 (10µg/ml). The concentration of IL-1β , IL-6 and IL-8 was 
measured by ELISA. The box plots represent the mean concentration of 5 patients for each cytokine 

































































Figure 5-2. A representative FACS plot showing mTNFα  expression in the mTNFα  transfected CHO 
cells compared to the mock transfected CHO cells.  
 
 
Figure 5-3. CHO cells transfected with mTNFα  showed a mean mTNFα  expression of 74.3% and the 
standard deviation. CHO cells transfected with mTNFα  were analysed 3 times by FACS to assess 




























Figure 5-4. Apoptosis is not increased in mTNFα  transfected CHO cells with infliximab compared to 
IgG1. A representative FACS showing CHO cells after 24 hour incubation with infliximab (10µg/ml) 
or IgG1 (10µg/ml) and the percentage apoptotic cells calculated by flow cytometry using Annexin V 







Figure 5-5. Apoptosis is not increased in CD14-ve activated PBMCs incubated with infliximab 
compared to IgG1 or etanercept.  Two experiments in which CD14-ve PBMCs activated with anti 
CD3/28 antibody for 48 hours and then incubated with IgG1 (10µg/ml), infliximab (10µg/ml) and 
etanercept (10µg/ml). Apoptosis (Annexin V +ve/ PI-ve cells) was quantified by flow cytometry. The 
percentage of apoptotic cells are shown above each FACS plot; IgG1 14.8% and 33.9%; infliximab 





Figure 5-6. There was no increase in apoptosis in unstimulated CD3+ LPMCs of inflamed CD with 
infliximab compared to IgG1. LPMCs were isolated and incubated with infliximab (10µg/ml) or IgG1 






Figure 5-7. GW280264X does not increase apoptosis in PBMCs incubated with infliximab. PBMCs 
from healthy controls were incubated for 48 hours with anti-CD3/ anti CD28 (1µg/ml) antibody with 
and without GW280264X 10µM. Infliximab (100µg/ml) or IgG1 (100µg/ml) was then added for 24 
hours before staining cells with Annexin V and Propidium Iodide and analysed by flow cytometry . 
Figure shows the mean of 3 experiments and the standard deviation. A significant difference was seen 
between IFX and IFX +GW280264X however there was also an increase seen in GW280264X +IgG1. 
Therefore this difference is not due to IFX. *=P<0.05  
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5.6 Discussion 
The aim of this chapter was firstly to elucidate whether infliximab reduces pro-
inflammatory cytokines. No change in the concentration of IL-1β, IL-8 or IL-6 
was detected ex-vivo. This is inconsistent with other studies. Nesbitt et al., 
(2007) showed a reduction in IL-1β in PBMCs following incubation with LPS 
although PBMCs were initially incubated with infliximab or IgG1 before the 
addition of LPS. Petito et al., (2016)  recently showed a reduction in IL-6 and 
IL-8 in the supernatant of colonic biopsies incubated with infliximab. 
 
The second aim was to establish the contentious issue of apoptosis with 
infliximab. Apoptosis was not seen in the mTNFα transfected CHO cell line in 
this study. Preliminary experiments showed that the CHO cell line expressed 
mTNFα and CHO cell lines are recognised for their robust nature in vector 
expression (Meleady et al., 2008). Ten Hove et al., (2002a) showed apoptosis in 
a Jurkat cell line with infliximab. 
  
Apoptosis was not seen in this study in PBMCs or LPMCs with infliximab or 
etanercept. Aghnolt et al., (2001) did not show apoptosis in colonic cultures 
from IBD patients. However apoptosis has been shown in PBMCs and LPMCs 
with infliximab (Nesbitt et al., 2007, Van den Brande., 2004, Di Sabatino et al., 
2004) using Annexin V/PI to measure apoptosis. More recently Eder et al., 
(2013) failed to show apoptosis in uninflamed biopsies following infliximab or 
adalimumab using immunohistochemical analysis. Inflamed biopsies were not 
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sampled. (Atreya et al., 2011) proposed a possible explanation for the detection 
of apoptosis when they showed apoptosis in TNFRII expressing CD4+ lamina 
propria T cells following incubation with mTNFα expressing CD14+ cells. 
However in this study, there was no apoptosis detected when PBMCs activated 
with P/I were incubated with the TACE inhibitor GW280264X and infliximab. 
Although the expression of mTNFα on CD14+ cells had not increased, which 
may have been an explanation for failing to show apoptosis. It is acknowledged 
that the sample size is small. 
This study did not support two of the proposed mechanisms of action of 
infliximab in IBD. Vossenkaemper et al., (2014) showed increased 
phosphoprotein expression in IBD using phosphoarrays. The next step was to 
elucidate whether infliximab reduced inflammation in IBD by their effect on 




6 The Effect of Anti-Tumour Necrosis Factor Antibodies on 
Receptor Tyrosine Kinase Phosphorylation 
6.1 Introduction 
Infliximab is effective in reducing inflammation in IBD and increasing the time 
between relapses (Van Dulleman et al., 1995), (Targan et al., 1997), (Rutgeerts 
et al., 1999). However the mechanisms of action are still not clear. It has been 
suggested that it induces T cell apoptosis in the inflamed gut (ten Hove et al., 
2002), (Van den Brande et al., 2003), kills cells expressing mTNFα by ADCC 
(Nesbitt et al., 2007), or kills them by complement activation (Mitoma et al., 
2008), (Arora et al., 2009). It has also been suggested that infliximab induces 
regulatory macrophages (Vos et al., 2011). Initially it was considered that TNFα 
was a master cytokine and when made by activated macrophages fed back and 
induced the production of other inflammatory molecules such as IL-6 or IL-1-β. 
(Butler et al., 1994). If this is indeed the case then it would be expected that 
infliximab would inhibit many of the downstream signalling pathways 
associated with cytokine driven inflammation. 
Receptor tyrosine kinases (RTK) are a family of receptors that signal primarily 
through phosphorylation events leading to a cascade of signalling pathways 
downstream which control cell signalling, the cell cycle, migration as well as 
cell proliferation and differentiation. Receptor tyrosine kinases (RTK) include 
Eph proteins, EGFR, PDGFR. The RTK families, which have been shown to be 
involved in the gut, are discussed in more detail below. 
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The Erythropoietin producing hepatocellular (Eph) receptor tyrosine kinases are 
the largest family of RTK. Eph proteins are expressed on almost all cells and are 
involved in wound healing and maintenance of intestinal cell populations. Eph 
proteins are divided into two subgroups –A and B. With few exceptions Eph A 
receptors bind to Ephrin A ligands and Eph B receptors to Ephrin B ligands. Eph 
A and B are similar in structure; extracellularly they have a ligand binding 
domain and a cys- rich domain (encompassing Sushi and Epidermal Growth 
Factor domain) and 2 fibronectin bound domains. Intracellularly a 
transmembrane region, a tyrosine kinase domain, the sterile alpha motif and the 
PDZ (postsynaptic density protein 95, discs large 1, and zonula occludens 1) 
domain. The interaction between Eph receptors and Ephrin ligands result in 
phosphorylation of tyrosine residues located between the transmembrane and 
tyrosine kinase domains.  
Ephrin ligands are unusual for RTK ligands because they are membrane bound 
rather than soluble. Ephrins can be divided into 2 two subsets; named A and B, 
based on their molecular structure; A-Ephrins are bound to the cell membrane by 
a glycosyl-phosphatidylinositol (GPI) anchor; B-Ephrins are transmembrane 
proteins (Pasquale., 1997). The binding of the Eph proteins and the Ephrin 
ligands direct collaborative cell movements by cell-cell signalling (Drescher., 
2002). Eph-Ephrin signalling is vital embryologicaly in axonal and vascular 
development (Flanagan and Vanderhaeghen, 1998), (Gale and Yancopoulos, 
1999). In the intestine Eph-Ephrins interactions organise the position of cells 
within the intestinal epithelial crypts (Batlle et al., 2002) and cell migration up 
the crypts by changing the expression of Eph receptors (Poliakov et al., 2004). 
(Holmberg et al., 2006) showed that Eph B receptors on progenitor cells 
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coordinate migration and proliferation in the stem cell niche. Thus they are 
likely to play an important role in the regenerative capacities in the gut following 
damage. In IBD the damage leads to massive increases in epithelial renewal as 
the gut tries to cover over ulcers with new epithelium. Interestingly Hafner et al., 
(2005) showed an up-regulation of Eph B2 receptor expression in both lesional 
and peri-lesional epithelial cells of IBD patients. 
Epidermal Growth Factor Receptors (EGFR) are cell surface growth receptors 
widely expressed in the intestinal tract on the apical and basolateral surface of 
villus enterocytes (Avissar et al., 2000). When EGF binds to EGFR the receptor 
dimerises resulting in the autophosphorylation of the EGFR RTKs which 
triggers various signalling pathways downstream. The signalling pathways 
involved include Ras/MAPK, phospholipase C/protein kinase C, and STATS 
signal pathways (Diegelmann et al., 2012). The signalling pathways play a vital 
role in cellular proliferation and differentiation that help in intestinal 
development and mucosa repair (Wee et al., 2015). EGFR expression is present 
in 60-80% of sporadic colorectal cancer (CRC) (Ciardiello and Tortora, 2003) 
and EGFR inhibitors appear to be effective in the treatment of CRC. There is 
also an increase in EGFR expression in IBD associated cancer (Svrcek et al., 
2007).  
The fibroblast growth factor receptors (FGFRs) are a family of tyrosine kinases, 
which consist of four members FGFR1, FGFR2, FGFR3 and FGFR4 which are 
very similar structurally (Touat et al., 2015). The extracellular component 
consists of two or three immunoglobulin-like structures which are required for 
FGF binding, an acidic region and a heparin-binding region (Brooks et al., 
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2012). Phosphorylated tyrosine kinase sites on the transmembrane region act as 
docking sites for various adaptor proteins. The proteins are then phosphorylated 
by the activated FGFR and stimulate four possible signalling pathways 
downstream; PLC, JAK, PI3K and GRB2. The result is a regulation of cell 
proliferation, differentiation, migration and survival (Beenken and Mohammadi, 
2009), (Ornitz, 2000) and plays a role in embryonic development and wound 
healing (Oladipupo et al., 2014). The association between FGFRs’ dysregulation 
and tumorigenesis has led to the development of a large number of FGFR 
inhibitors in cancer treatment (Turner et al., 2010). 
Platelet derived growth factor (PDGF) is a major growth factor which plays a 
central role in the repair process. PDGF transduces signals by binding to PDGF 
receptor- of which there are two- PDGFR-α and PDGFR-β which are tyrosine 
kinase receptors. They are structurally similar with 5 Ig-like domains 
extracellularly, two of which form the binding site for PDGF. In the intracellular 
region, up to eleven tyrosine kinase residues are located. These sites are 
autophosphorylated on binding of PDGF and trigger a range of signaling 
cascades such as ERL MAPK. Defects in PDGFR signaling has been associated 
with various cancers (Medves and Demoulin, 2012). 
The mitogen-activated protein kinase (MAPK) pathways are important in 
controlling inflammation, cell differentiation, cell growth and malignancy. There 
are three major constituents; the extracellular signal-regulated kinases (ERKs) 
such as p42/p44, the c-Jun N-terminal kinases, and the p38 MAPKinases. Apart 
from ERK 3 and 4 and NLK, full activation of MAPKinases requires dual 
simultaneous phosphorylation of threonine and tyrosine within a Threo-X-Tyro 
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motif where X is a specific amino acid. The amino acid varies between 
MAPKinases and confers specificity for the upstream kinase. Phosphorylation 
results in a conformational change in the protein exposing the kinase active site 
and enable substrate binding (Chen et al., 2001). Activation of the signaling 
cascade can be triggered by a wide range of stimuli, in general ERKs are 
activated by mitogens and differentiation signals whilst Jun and MAPK are 
activated by cellular stresses (Riemann et al., 2015). TNF can activate all three 
groups (including hormones, growth factors, PAMPS, cytokines and 
environmental stresses and cellular stress particularly by TNFα).  
Increased expression of ERK 1 and 2, p38 and MAPK are seen in IBD patients 
compared to controls  (Waetzig et al., 2002). Levels of activated p38 MAPK 
were found to be raised in the inflamed mucosa of patients with IBD  (Docena et 
al., 2010) and inhibitors of MAPK reduce phosphorylated MAPK in biopsies 
cultured ex vivo from patients with IBD (Docena et al., 2010). Hommes et al., 
(2002) showed that a Jnk and p38 MAPK inhibitor given for 12 days reduced 
MAPK phosphorylation when tested in vitro on colonic biopsies. After 4 weeks, 
67% showed a clinical response and a significant reduction in CDAI.  
The Jak/ Signaling transducer and activation of transcription (STAT) 3 pathway 
is used by cytokines such as IL-6 (De Simone et al., 2015) and IL-10  (Lejeune 
et al., 2002). On binding of cytokines to its membrane receptor a conformational 
change occurs in associated JAK molecules resulting in autophosphorylation and 
a second phosphorylation on the cytokine receptor. Subsequently docking sites 
for STAT are exposed which are also phosphorylated and translocate to the 
nucleus regulating transcription of various genes (O’Shea et al., 2004). STAT 5 
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is involved in the development of different T cell subsets, specifically T regs 
(Yao and Shao., 2007). The role of STAT 3 in IBD is well documented (Kaur et 
al., 2016), (Zundler and Neurath, 2016), (Jauregui-Amezaga et al., 2015), and its 
expression is increased in both UC and CD lamina propria T cells (Mudter et al., 
2005). In addition a JAK1, 3 and 5 inhibitor  (Tofacitinib) shows efficacy in UC 
(Sandborn et al., 2012) although has not been shown to be more effective than 
placebo in CD (Panés et al., 2015). 
T cell subsets are important in IBD. How T cells are activated and differentiate 
into different subsets is of interest. ZAP-70 is a cytoplasmic tyrosine kinase 
mainly expressed in T cells and mediates T cell receptor (TCR) signaling. 
Following TCR engagement, Lck associated to CD4 is brought into proximity 
with the TCR enabling the phosphorylation of the ITAM motifs situated on the 
TCRζ chain. After ITAM binding, ZAP-70 is phosphorylated by Lck, activating 
ZAP-70  (Wang et al., 2010). ZAP-70 activation triggers a number of signalling 
cascades resulting in rearrangement of the T cell cytoskeleton, IL-2 synthesis 
and release and T cell proliferation (Boubek et al., 1996). Loss of function of 
expression of ZAP-70 in humans leads to SCID in which CD4+ T cells are 
nonfunctional and CD8+ T cells are absent (Elder et al., 1994). Bouzid et al 
recently showed an association between a ZAP-70 polymorphism and CD in a 
Tunisian population (Bouzid et al., 2013). A heterozygous mutation in ZAP-70 
was identified in a Chinese patient who developed early onset and recurrent 
infections as well as IBD amongst other autoimmune clinical manifestations 
(Liu et al., 2017).  
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The different efficacies of infliximab and etanercept in IBD have been discussed 
in chapter 5. The reasons for this difference is not yet understood and research is 
still needed to explain why etanercept, an anti-TNFα antibody is ineffective in 
CD whilst infliximab is effective.  
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6.2 Aims 
To use phosphoarrays to determine if the addition of TNFα neutralising agents 
to mucosal biopsies from patients with IBD ex vivo has any effect on RTKs. 
Accordingly the following experiments were carried out. 
1. The phosphorylation events in inflamed IBD biopsies incubated in 
infliximab were measured. Samples were initially snap frozen and stored 
at -80°C prior to cell lysis and phosphoarray. 
2. The phosphorylation changes in inflamed biopsies of UC and CD 




6.3 Materials and Methods 
6.3.1 Organ Culture of Intestinal Mucosal Biopsies 
Inflamed colonic biopsies obtained during colonoscopy were cultured (one 
biopsy per well) in 24 well plates (VWR International, Lutterworth, UK) in 
300µl of serum free HL-1 medium (Cambrex BioScience, Wokingham, UK) for 
24 hours at 37°C, in 5% CO2. At the start of the culture infliximab (5µg/ml; 
Remicade®, Schering-Plough, Welwyn Garden City, UK), etanercept (5µg/ml ; 
Enbrel®, Wyeth, Maidenhead, UK) or IgG1 were added.  The supernatant was 
collected after 24 hrs and stored at -80°C before undergoing cytokine array 
analysis. The biopsy was snap-frozen and stored at -80°C prior to cell lysis and 
phosphoarray. 
6.3.2 Phosphoarray 
Pathscan RTK signalling arrays (Cell Signalling Technology, Danvers, MA) 
were used to determine the phosphorylation status of receptor tyrosine kinases. 
One hundred microlitres RIPA buffer (containing 10µl/ml protease inhibiter and 
10µl/ml phosphatase inhibiter) was added to each biopsy on ice. The biopsy was 
then sonicated for 2-3 seconds three times before centrifugation for 10 minutes 
at 12000g at 4°C. The supernatant was aspirated and the protein concentration 
calculated using the Bradford assay. The supernatants were stored at -80°C.  
The PathScan RTK Signalling Antibody Array kit is a slide based antibody array 
based upon the sandwich immunoassay principle. It allows for the simultaneous 
detection of 28 receptor tyrosine kinases and 11 signalling nodes phosphorylated 
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at tyrosine or other residues. The manufacturer precoats the slide, with capture 
antibodies spotted in duplicate onto nitro-cellulose glass slides. A multi-well 
gasket is fixed onto the slide and 150µl of blocking buffer is introduced into 
each well. The slide is placed on a rocker at room temperature for 15 minutes. 
The blocking buffer is then decanted from each well and 150µl of sample lysate 
containing 75µg of protein is introduced into the well and incubated on a rocker 
at room temperature for two hours. The wells are then washed four times with 
array wash buffer for five minutes each before 150µl of Array Detection 
Antibody Cocktail is introduced and incubated for one hour. The slide is washed 
again four times and 150µl of streptavidin HRP is introduced into each well. The 
slide is washed and then removed from the gasket. Lumiglow and peroxide were 
then pipetted onto the slide, which was then exposed to X-ray film, and the pixel 
intensity quantified using Image J.  
6.4 Statistical Analysis 
Data was analysed using GraphPad Prism (GraphPad Software, San Diego, CA) 
software. Student’s paired t-test was used to compare two values from the same 
individual. P values of less than 0.05 were considered statistically significant. 
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6.5 Results 
6.5.1 The phosphorylation levels detected in inflamed CD and UC biopsies 
were high. 
Inflamed biopsies from five CD patients and four UC patients were incubated 
with IgG1 or infliximab for 24 hrs. The pixel intensities of healthy controls were 
studied in Vossenkaemper et al., (2014) in our group and shown to be low 
compared to IBD. Figure 6.1 shows the array after exposure to X ray film and 
the RTK map identifying the different RTKs on the array. The pixel intensity of 
inflamed CD and UC biopsies showed high phosphoprotein levels in the 
majority of phosphoproteins. Figures 6.2 and 6.3 show each of the biopsies’ 
phosphoprotein levels for CD and UC respectively as represented by a heatmap. 
There is some variation between the samples as well as between the different 
phosphoproteins from the same biopsy. The range varied from 0.01 (the value in 
TrkA and TrkB in CD2, CD3 and CD4) up to 78.4 (the value of Src in UC1). 
6.5.2 The phosphoprotein levels were higher in the UC individuals 
compared to the CD individuals. 
The mean pixel intensity in the CD biopsies and the UC biopsies for each 
receptor tyrosine kinase was greatest for the EGFR, FGFR, Insulin R and Stat 
families (19.36 in FGFR4 up to 39.04 in EGFR) (Figures 6.2 and 6.3,6.4 to 6.7). 
The mean pixel intensity was low in the NGFR and HGFR families (2.79 in 
TrkA and up to 10.67 in Ron/ MST1R) (Figure 6.2), in fact in 3 of the 
individuals the pixel intensity was the same as the background in these families 
(CD2, CD3 and CD4 in Figure 6.2).  
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6.5.3 There was a global reduction in phosphoprotein levels with 
infliximab in CD and UC biopsies. 
Figure 6.1 shows a representative slide of a CD biopsy with infliximab and IgG1 
and the array map for identification of RTKs. The relative pixel intensity is 
reduced in all phosphoproteins in each CD individual (Figure 6.2) and three out 
of four UC individuals (Figure 6.3).  
6.5.4 PDGFR, c-Kit, M-CSFR/CSF and FLT3 phosphoproteins in the 
PDGFR family were reduced significantly with infliximab. 
Four RTK were measured in the PDGFR family, which were c-Kit, FLT3, 
PDGFR and M-CSFR. The mean change in pixel intensity of all five CD and 
four UC individuals reduced in all four RTK (Figure 6.4). The reduction was 
significant in c-Kit (p=0.001), PDGFR (p=0.026), M-CSFR/ CSF (0.022) and 
FLT3 (p=0.008) (Figure 6.8). 
 
6.5.5 Infliximab significantly reduced the phosphoproteins Eph A2, Eph 
A3, Eph B1 and Eph B3 in IBD.  
Six RTKs from the Ephrin family were measured; Eph A1, Eph A2, Eph A3, 
Eph B1, Eph B3 and Eph B4. The mean pixel intensity in the phosphoproteins in 
the biopsies incubated in IgG1 and infliximab showed a reduction in all 
members in CD and in UC (Figure 6.4). The reduction in IBD biopsies was 
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significant in Eph A2 (p=0.002); Eph A3 (p= 0.02), Eph B1 (p=0.004), and Eph 
B3 (p=0.007) (Figure 6.9).  
 
6.5.6 Infliximab significantly reduced the phosphoproteins EGFR and 
HER2. 
Three phosphoproteins from the EGFR family were measured which were 
EGFR/ Erb1, HER2/ Erb2 and HER 3/ Erb3 and infliximab reduced the levels of 
each (Figure 6.5). The mean pixel intensity in the 5 CD biopsies was reduced 
from 39.04 to 27.70 and in the UC biopsies from 44.7 to 42.8. Together there 
was a significant reduction with infliximab in inflamed IBD biopsies in EGFR 
(p=0.02) and HER 2 (p=0.02) (Figure 6.10). The reduction in HER 3 was not 
significant.  
 
6.5.7 Infliximab significantly reduced the phosphoproteins FGFR3 and 
FGFR4. 
Three phosphoproteins from the FGFR family were measured, namely FGFR1, 
FGFR3 and FGFR4. Infliximab significantly reduced the levels in each 
phosphoprotein (Figure 6.5). FGFR3 reduced from 27.40 to 17.13 (p=0.016) and 
FGFR4 reduced from 19.40 to 10.20 (p=0.021) (Figure 6.11). The pixel intensity 
for each phosphoprotein in IgG1 and infliximab can be seen in Figure 6.11 
showing the reduction in all but one individual with infliximab. 
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6.5.8 Infliximab significantly reduced Axl, Tyro3, Tie2 and VEGFR 
phosphoproteins. 
The RTK measured in the Axl family were Axl and Tyro3. There was a 
significant reduction in Axl, Tyro and Tie2 and VEGFR when a paired t test is 
carried out on all IBD biopsies where p=0.001 (Axl), p=0.004 (Tyro3), p=0.001 
(Tie2) and p=0.003 (VEGFR) (Figure 6.6 and 6.12). 
  
6.5.9 Infliximab significantly reduced phosphoproteins p44/MAPK, S6 
Ribosomal protein and c-Abl in inflamed IBD biopsies. 
Infliximab reduced phosphorylation of p44/MAPK and s6 ribosomal protein and 
c-abl which is significant in the IBD biopsies in p44/MAPK (p=0.015), S6 
Ribosomal protein (p=0.026) and c-abl (p=0.024) (Figure 6.7 and 6.13).  
 
6.5.10 Infliximab significantly reduces phosphoproteins IRS-1 and Zap-70 
in CD biopsies. 
Although the reduction in phosphoprotein intensity in IBD biopsies together is 
not significant, when a paired t test is applied to the CD biopsies alone the 
reduction is significant where p=0.007 in Zap-70 and p=0.017 in IRS-1 (Figure 
6.13 and 6.14). 
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6.5.11 Infliximab significantly reduced phosphoproteins Akt/PKB/Rac on 
Ser 473 in inflamed IBD biopsies. 
There was a significant reduction in Ser473 in inflamed IBD biopsies (p=0.007) 
(Figure 6.7 and 6.15). In the CD biopsies alone however there was a significant 
reduction in Src (p=0.02), Lck (p=0.015) and Sat 1 (p=0.016) (Figure 6.16). 
 
6.5.12 Etanercept reduces PDGFR, c-Kit FLT3 and CSFR phosphorylation 
in inflamed IBD biopsies 
The phosphorylation intensities were high in the IBD biopsies with IgG1, seen in 
the heatmap showing the changes in all four of the inflamed IBD biopsies (3 UC, 
1 CD) (Figure 6.17) There was a reduction in receptors in the PDGFR family, 
including PDGFR, c-Kit, FLT3 and CSFR, although the reduction is not 
significant. There was no change in the phosphorylation of the other RTKs 








Figure 6-1 Phosphoarray showing a sample chemiluminescent film of IgG1 and infliximab and the 
array map with the RTKs and signaling nodes listed. IBD biopsies were incubated for 24 hours with 
IgG1 (5µg/ml) or infliximab (5µg/ml) and the biopsies then lysed and analysed for phosphorylation 




Figure 6-2. Infliximab reduces the phosphorylation in all RTKs measured in CD biopsies. A heatmap 
representing the mean pixel intensity measured in the inflamed biopsies of five CD individuals 




































































Figure 6-3. Infliximab reduces the phosphorylation in all RTKs measured in UC biopsies. A heatmap 
representing the mean pixel intensity measured in the inflamed biopsies of four UC individuals 












































































Figure 6-4 Infliximab reduces phosphorylation in IBD explants in PDGFR and Eph family. Mean 
pixel intensity and the standard deviation from explants of 5 CD and 4 UC patients incubated for 24 
































































Figure 6-5 Infliximab reduces phosphorylation in IBD explants in EGFR anf FGFR family. Mean 
pixel intensity and the standard deviation for 18 receptor tyrosine kinases from explants of 5 CD and 











































































































Figure 6-6. Infliximab reduces phosphorylation in IBD explants in RTKs. Mean pixel intensity and 
the standard deviation for receptor tyrosine kinases from explants of 5 CD and 4 UC patients 













































































































































Figure 6-7. Mean pixel intensity and the standard deviation of RTKs and signalling nodes from 








































































































































































Figure 6-8. All phosphoproteins in the PDGFR are reduced significantly with infliximab. Five CD 
and 4 UC biopsies were incubated for 24 hours with infliximab (5µg/ml) or IgG1 (5µg/ml) and the 














































































































Figure 6-9 EphA2, EphA3, EphB1 and Eph B3 in the Eph family are significantly reduced in IBD 
biopsies with infliximab. Five CD and four UC biopsies were incubated for 24 hours with Infliximab 
(5µg/ml) or IgG1 (5µg/ml) and the phosphoprotein expression measured by calculating the pixel 































































































































































Figure 6-10. Infliximab reduced the phosphoprotein levels of EGFR and HER 2 in the EGFR family 
significantly in IBD biopsies. Five CD and four UC inflamed biopsies were incubated for 24 hours 
with infliximab (5µg/ml) or IgG1 (5µg/ml) and the phosphoprotein expression measured by 

















































































Figure 6-11. Infliximab reduced the phosphoprotein levels of FGFR3 and FGFR4 significantly in 
inflamed IBD biopsies. Five CD explants and four UC were incubated for 24 hours with infliximab 
(5µg/ml) or IgG1 (5µg/ml) and the phosphoprotein expression measured by calculating the pixel 



















































































Figure 6-12. Infliximab significantly reduces Axl, Tyro3, Tie2/TEK and VEGFR in inflamed IBD 
biopsies. Five CD and four UC explants were incubated for 24 hours with Infliximab (5µg/ml) or 
IgG1 (5µg/ml) and the phosphoprotein expression measured by calculating the pixel intensity. * = 















































































































Figure 6-13. Infliximab significantly reduces the phosphoproteins p44/ MAPK, S6 Ribosomal Protein 
and c-Abl in inflamed IBD biopsies. Five CD and four UC biopsies were incubated for 24 hours with 
Infliximab (5µg/ml) or IgG1 (5µg/ml) and the phosphoprotein expression measured by calculating 





































































































































Figure 6-14. Infliximab significantly reduces the phosphoproteins IRS-1 and Zap-70 in inflamed CD 
biopsies. Five CD explants and four UC explants were incubated for 24 hours with Infliximab 
(5µg/ml) or IgG1 (5µg/ml) and the phosphoprotein expression measured by calculating the pixel 





































































































Figure 6-15. Infliximab significantly reduces the phosphoproteins Ser473 in inflamed IBD biopsies. 
Five CD and four UC biopsies were incubated for 24 hours with Infliximab (5µg/ml) or IgG1 

































































































































































Figure 6-16. Infliximab significantly reduced Src, Lck and Stat 1. Five CD explants were incubated 
for 24 hours with Infliximab (5µg/ml) or IgG1 (5µg/ml) and the phosphoprotein expression measured 








































































































Figure 6-17. Etanercept does not reduce the phosphorylation intensity of IBD biopsies. Etanercept 
(5µg/ml) or IgG1 (5µg/ml) were added to inflamed IBD biopsies (3 UC and 1CD) for 24 hours. The 











































































Figure 6-18. Etanercept does not reduce phosphorylation in IBD explants in PDGFR and Eph Family 
Mean pixel intensity and standard deviation for receptor tyrosine kinases from explants of 1 CD and 









































































































































Figure 6-19. Etanercept does not reduce phosphorylation in IBD explants in EGFR and FGFR family 
Mean pixel intensity and standard deviation for receptor tyrosine kinases from explants of 1 CD and 









































































































Figure 6-20 Etanercept does not reduce phosphorylation in IBD explants in RTKs. Mean pixel 
intensity and standard deviation for 18 receptor tyrosine kinases from explants of 1 CD and 3 UC 







































































































































Figure 6-21 Etanercept does not reduce phosphorylation in IBD explants in signalling proteins. Mean 
pixel intensity and standard deviation for 18 receptor tyrosine kinases from explants of 1 CD and 3 














































































































































































Vossenkämper et al., (2014) showed increased phosphorylation in CD and UC 
inflamed biopsies compared to controls. UC biopsies also showed a greater 
relative phosphorylation intensity than CD biopsies (Vossenkämper et al., 2014). 
This is understandable as there is a great deal of repair and regeneration required 
in IBD as a result of mucosal inflammation. 
The RTKs involved in repair and wound healing are the EGFR, FGFR and 
PDGFR families. Whilst previous observations have included activity of RTKs 
in IBD these results show for the first time that infliximab significantly reduces 
the phorphorylation activity.  
MAPK is known to be activated by TNF and increased expression of ERK 1 and 
2 (also called p44/MAPK) and p38 MAPK was shown in IBD by Western blot 
and immunohistochemistry of IBD biopsies (Waetzig et al., 2002). Waetzig et 
al., (2002) also showed a reduction in ERK 1 and 2 (p44/MAPK) expression 
following glucocorticoid treatment. 
ERK 1 and 2 levels have not been measured in IBD with infliximab, however 
Faurschou et al., (2008) showed a reduction in ERK 1/2 expression in 
keratinocytes following UVB damage. A reduction in Akt Thre and Akt Ser-473 
was also shown similar to this study. 
PDGF is a major growth factor which plays a central role in the repair process. 
PDGFR was significantly reduced in IBD biopsies (P=0.026) after 24 hours. 
Kumagai et al., (2001) showed increased expression of PDGFR by in situ 
 162 
hybridization and immunohistochemistry on surgical IBD resections in active 
inflammation as well as areas of fibrosis adjacent to the ulcer base. The changes 
with infliximab have not been shown previously. 
CSFR-1 RNA transcripts have been shown to be increased in IBD when 
measured by real time PCR (Franze et al., 2016). Franze et al., (2016) also used 
immunohistochemistry to show up-regulation of this receptor in epithelial and 
lamina propria mononuclear cells. This is consistent with an increased 
phosphorylation intensity seen by Vossenkaemper et al., (2014). However the 
effect of infliximab has not been looked into previously. 
This study shows high phosphorylation of EGFR in inflamed colon. This was 
also shown by Hardbower et al., (2017) when they looked specifically at EGFR 
phosphorylation in macrophages. There was increased phosphorylation 
compared to inactive colon in IBD. 
The role of Eph receptors in the intestinal crypt has been shown recently by 
Jurek et al., (2016) and previously by Holmberg et al., (2006). Cooperation 
between Eph A and B recptors is required for mitogenesis in the stem cell niche 
(Jurek et al., 2016). Hafner et al., (2005) showed increased expression of Eph B2 
in CD biopsies. Eph B2 was not included in the phosphoarray used however Eph 
A2, EphB1 and EphB3 were shown to be raised in IBD and reduced with 
infliximab. It is not possible to say whether the reduction in Eph receptor 
phosphorylation is due to an improvement in healing by infliximab and therefore 
a down regulation of the proliferation of progenitor cells or whether infliximab 
directly effects Eph phosphorylation. No other studies have looked at the effect 
of infliximab on Eph receptors. 
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ZAP-70 was shown to be significantly reduced by infliximab in the CD samples 
but not in the UC samples. Bouzid et al., (2013) showed a single nucleotide 
polymorphism rs13420683 was associated with CD but not UC in a Tunisian 
population supporting the importance of T cell signaling in CD. 
It is interesting that the phosphorylation intensity is not reduced with etanercept. 
The phosphorylation intensity is high showing that the biopsies were taken from 
inflamed areas. Patients also were anti-TNF naïve. Sandborn et al., (2001) 
showed that etanercept was ineffective in CD in a pilot study. This was 
supported more recently with the lack of improvement seen in ankylosing 
spondylitis- associated intestinal inflammation following treatment with 
etanercept compared to infliximab or adalimumab (Chitul et al., 2017). 
Etanercept does not bind to mTNFα with the same avidity as infliximab (Nesbitt 
et al., 2007), (Shealy et al., 2010), but binding to sTNFα is similar to infliximab 
(Nesbitt et al., 2007). This study does not indicate how infliximab reduces the 
phosphorylation of RTKs, but it is possible that this is via mTNFα rather than 
sTNFα.  However another possible explanation for the lack of effect by 
etanercept is related to the matrix metalloproteinases (MMPs). Biancheri et al., 
(2015) showed that etanercept is extremely senstitive to breakdown by MMP 3 
and 12 which are in excess in the inflamed mucosa in IBD. The findings indicate 
the possibility that RTKs may be significant signaling pathways of clinical 
benefit in the treatment of IBD. 
Having shown a significant change in RTKs using phosphoarrays, the next step 
was to use a cytokine array to elucidate changes in a large number of cytokines 
ex vivo by infliximab. 
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7 The Effect of Anti-Tumour Necrosis Factor Antibodies on 
Cytokine Production in IBD biopsies 
7.1 Introduction 
Crohn’s disease has characteristics of a Th1 type immune response with 
increased concentration of IFNγ and IL-12 (Breese et al., 1994), (Monteleone et 
al., 1997) and overexpression of Th1 transcription factors such as Stat-1 and T-
bet (Neurath et al., 2002). UC however displays Th2 characteristics, increased 
production of IL-5, although not IL-13 as originally thought (Biancheri et al., 
2014). Both CD and UC have increased numbers of Th17 cells which have the 
potential to secrete IL-17A, IL-17F, IL-21, IL-22 and IL-26 (Rovedatti et al., 
2009), (Chen and Sundrud, 2016).  
 
Tumour Necrosis Factor alpha (TNFα) is abundant in both CD and UC (Breese 
et al., 1994). The most successful anti-cytokine treatment  for IBD in the last 20 
years has been  anti-TNFα antibodies. Infliximab is effective in the treatment of 
inflammatory and fistulising CD as well as in UC (Targan et al., 1997), (Sands, 
2001). However infliximab is not effective in almost half of patients and with 
others the response wanes over time (Rutgeerts et al., 2009). Understanding the 




The mechanisms of action of anti-TNFα antibodies are not fully understood. 
TNFα is thought to act as a master cytokine released by macrophages, which 
feeds back to the cell and leads to increased secretion of other pro-inflammatory 
cytokines. Neutralisation of mTNFα has been shown to result in a reduction in 
pro-inflammatory cytokines such as IL-6, IL-1β and IL-8 (Butler et al., 1995, 
(Nesbitt et al., 2007). (Mitoma et al., 2005) showed the induction of IL-10 in a 




To establish whether the addition of infliximab to mucosal biopsies influences 
the production of other cytokines and chemokines, the following experiments 
were carried out 
1. Inflamed biopsies of CD and UC patients were incubated in the presence 
of anti-TNF antibodies and the supernatants analysed using a cytokine 
array panel.  
2. The results between infliximab and etanercept were compared. 
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7.3 Materials and Methods 
7.3.1 Organ Culture of Intestinal Mucosal Biopsies 
 Inflamed colonic biopsies obtained during colonoscopy were cultured (one 
biopsy per well) in 24 well plates (VWR International, Lutterworth, UK) in 
300ul of serum free HL-1 medium (Cambrex BioScience, Wokingham, UK) for 
24 at 37°C, in 5% CO2. At the start of the culture infliximab (Remicade®, 
Schering-Plough, Welwyn Garden City, UK; 5µg/ml), etanercept (Enbrel®, 
Wyeth, Maidenhead, UK; 5µg/ml) or IgG1 were added.  The supernatant was 
collected after 24 hrs and stored at -80°C before undergoing cytokine array 
analysis.  
7.3.2 Cytokine Array Analysis 
 A human cytokine array panel A (R and D Systems, Abingdon, UK) was used 
to determine changes in 38 cytokines and chemokines simultaneously in the 
supernatants. Nitrocellulose membranes were precoated with capture antibodies 
in duplicate.  The membrane is then placed in a multi-well dish containing 1ml 
of blocking buffer for 1 hour at room temperature on a rocking platform. Array 
buffers containing a buffered protein base provided by the manufacturer are 
added to 250µl of  supernatant to make a total of 1ml and 15µl of detection 
antibody  cocktail added, mixed and incubated for 1 hour at room temperature. 
The buffer is then aspirated from the wells and the sample/ antibody mixtures 
added onto the nitrocellulose membranes. The membranes are incubated 
overnight on a rocking platform at 4°C. The membranes were then removed and 
placed into plastic containers and rinsed with  20ml wash buffer before being 
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washed for 10 minutes three times. Strepdavidin HRP (1 in 200) was then added 
to each well with the membranes and incubated for 30 minutes. The membranes 
were washed as before and placed on a plastic sheet. One ml chemilumescent 
mix was added and the membranes exposed on X-ray film and pixel intensity 
quantified using Image J. 
7.3.3 Statistical Analysis 
Data was analysed using GraphPad Prism (GraphPad Software, San Diego, CA) 
software. Student’s paired t-test was used to compare two values from the same 
individual. P values of less than 0.05 were considered statistically significant. 
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7.4 Results 
7.4.1 There is a high expression of pro-inflammatory cytokines in IBD 
biopsies 
Figure 7.1 shows the expression of cytokines without treatment and the heatmap 
in Figure 7.2 shows the high expression of proinflammatory cytokines in 
biopsies cultures with IgG1. The cytokines which have the highest expression 
are G-CSF, CXCL1, sICAM-1, IL-1ra, IL-6, IL-8, IL-16, IL-17, IL-27, MIF, 
Serpin E and CCL5 (Figures 7.1 and 7.2).  
 
7.4.2 Infliximab reduces C5/5a, CD40 ligand, IL-1ra, IL-2, IL-4, IL-8, IL-
16, MIF, CCL5, IL-32a, CXCL10, CXCL11, CXCL12, TNFα  and 
sTREM1.  
There was a reduction in a large number of cytokines although the change was 
not significant. The fold change seen with infliximab was calculated by dividing 
the mean pixel intensity with IgG1 by the mean pixel intensity with infliximab. 
Table 7.1 shows six cytokines reduced by 2 to 5 fold namely C5/C5a (2.2), IL-
10 (3.5), CCL5 (2.7), CXCL12 (3.2), TNFα (4) and sTREM1 (2.2)(2 CD and 1 
UC patient) (Figure 7.3). 
7.4.3 Etanercept reduces CD40 ligand, IL-6, IL-8, IL-17, IL-27, CCL3, 
CCL5 and TNFα. 
Etanercept reduced the mean cytokines in the two CD patients tested. Although 






Figure 7-1. Infliximab and etanercept reduced most of the cytokines tested. Etanercept reduced G-
CSF, IL-6 and IL-8 which were unaffected by infliximab in this patient. Membranes from cytokine 
array testing cytokine array from supernatants of CD biopsies incubated for 24 hours with IgG1 




 Figure 7-2There is a high expression of pro-inflammatory cytokines in the controls which show a 
small reduction with infliximab. A heatmap showing inflamed biopsies from 2 CD patients and 1UC 





























































Figure 7-3. Infliximab reduces C5/5a, CD40 ligand, IL-1ra, IL-2, IL-4, IL-8, IL-16, MIF, CCL5, IL-
32a, CXCL10, CXCL11, CXCL12 TNFα  and sTREM1. Mean change in cytokine concentration in 
the supernatants of inflamed IBD biopsies (2 CD and 1 UC patient). Cytokine expression was 
measured by pixel intensity calculation on a cytokine array on the supernatants of biopsies incubated 
























































































































































Table 7.1. The fold change in cytokine intensity with infliximab and IgG1 in the supernatants of IBD 
biopsies incubated for 24 hours. 








































 Figure 7-4 Etanercept reduces CD40ligand, IL-6, IL-8, IL-17, IL-27, CCL3, CCL5 and TNFα . Mean 
chemokine expression in the supernatants of 2 CD patients in which biopsies incubated in etanercept 


























































































































































7.6 Discussion  
The development, growth, activation and function of the innate and adaptive 
immune response is controlled largely by cytokines. A fine balance exists to 
maintain tissue integrity.  In IBD, in which the immune system is dysregulated 
infliximab is effective in achieving mucosal healing (Corica and Romano, 2017). 
It was hypothesized that infliximab would affect the concentrations of a wide 
range of cytokines and chemokines. By using a cytokine array, the role of new 
cytokines might be discovered. 
The cytokines CCL5 (RANTES), MIF, IL-8 and IL 1ra reduced with infliximab 
in IBD biopsies. Increased concentrations of CCL5, MIF, IL-8 and IL1ra have 
previously been associated with IBD (McCormack et al., 2001), (Ansari et al., 
2006), (Singh et al., 2016), (Neurath, 2014), (Daryani et al., 2015). This is the 
first study to show a reduction in the CCL5 and MIF with infliximab in IBD. 
Etanercept did not reduce MIF but there was a reduction in CCL5. The reduction 
seen with infliximab is not significant. One possibility for this is the numbers are 
very small (2 CD and 1 UC patient). The other possibility is that the time frame 
was too short. Vossenkämper et al., (2014) used a similar cytokine array to test a 
CD3 antibody otelixumab. Biopsies were incubated for 48 hours before the 
supernatants tested for cytokines. In the previous chapter, a significant reduction 
was seen in a wide range of RTKs which are involved in the regulation of 
cytokines and therefore it is reasonable to expect a change in cytokines. 
Incubating the IBD biopsies for 48 hours and increasing the number of samples 
would therefore be an important next step. 
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8 General Discussion 
 
Tumour Necrosis Factor alpha is central to the immunopathogenesis of 
inflammatory bowel disease. It is initially expressed on the cell surface as a 
trimer and cleaved from the cell surface by TNFα Converting Enzyme (TACE) 
to release the soluble trimeric form of the cytokine.  The aim of this study was to 
establish whether pharmacological and endogenous TACE inhibitors increase 
membrane TNFα with reciprocal reduction in soluble TNFα and identify any 
changes in other pro-inflammatory cytokines. Atreya et al., (2014) have shown 
an association between mTNFα expression on macrophages in the gut and the 
clinical response to adalimumab, another  anti-TNF antibody  used to treat IBD. 
In animal models, neutralisation of mTNFα is also important in improving colitis 
(Perrier et al., 2013). 
The TACE inhibitors tested were a broad spectrum MMP inhibitor called 
Marimastat which has been reported to inhibit TACE, (Tsuji et al., 2002), the 
endogenous inhibitor TIMP-3 (Monteleone et al., 2012), and a specific inhibitor, 
GW280264X, which was a gift from Prof Stefan Rose-John. All TACE 
inhibitors showed a reduction in sTNFα by activated PBMCs and by explants of 
IBD mucosa cultured ex vivo. An increase in mTNFα was also seen in PBMCs 
activated with anti CD3/28 antibody in the presence of GW280264X. With the 
exception of Monteleone et al., (2012), who showed an increase in mTNFα 
expression on LPMCs from patients with IBD cultured with TIMP-3, most of the 
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studies with TACE inhibitors in IBD focus on sTNFα and not mTNFα. This 
study therefore adds to the work by Monteleone et al., (2012) in showing the 
effect of TACE inhibitors on mTNFα specifically. There was no change in the 
production of other pro-inflammatory cytokines by inflamed biopsies ex vivo, 
namely IL-1β, IL-6 and IL-8. This study does not indicate if TACE inhibitors 
have a pro- or anti-inflammatory effect or any other downstream effect as a 
result of increasing mTNFα expression. It also suggests that reducing TNF-alpha 
production has no effects on other cytokines. Although some studies have shown 
a reduction in pro-inflammatory cytokines with TACE inhibitors (Monteleone et 
al., 2012), (Sharma et al., 2014), Fréour et al., (2009) showed an increase in gut 
epithelial permeability when cultured with TIMP-3. A TACE knockout patient 
suffers from recurrent mild gut inflammation  but the etiology of this 
inflammation is not known (Blaydon et al., 2011).  A shortcoming of this study 
is that the number of samples was quite small and in cases where trends did not 
reach significance, increasing the number of samples studied would possibly 
show significant results. 
Infliximab, an anti-TNFα antibody, has revolutionised the treatment of IBD 
(Kuek et al., 2007). However up to half of patients fail to respond and up to a 
third of patients lose response over time. The mechanisms of action are also 
incompletely understood. There is therefore a need to understand the 
mechanisms by which infliximab induces remission to help develop further 
treatments for IBD. Two of the suggested mechanisms of action were tested in 
this study, namely neutralisation of TNFα and subsequent reduction in other pro-
inflammatory cytokines, and apoptosis. 
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The concentration of IL-1β, IL-8 or IL-6 did not change in inflamed IBD 
biopsies incubated with infliximab ex-vivo.  Taken together with the fact that 
TACE inhibitors also did not reduce the production of other cytokines, it appears 
that in the gut, the paradigm originally thought to explain the mode of action of 
infliximab does not apply. Specifically it was suggested that TNFα was a master 
cytokine which when made by macrophages fed back and increased the 
production of other pro-inflammatory cytokines (Ogata and Hibi, 2003). The 
implication of these results is that it supports the use of other anti-cytokine 
therapies in patients who become infliximab unresponsive, such as anti-IL-6 or 
anti-IL-6R. 
The second aim was to establish the contentious issue of apoptosis induction 
when mTNFα binds infliximab. This study did not show apoptosis either in a 
TNFα transfected cell line which expressed high levels of mTNFα or using 
activated  PBMCs. Some studies have shown that infliximab induces apoptosis 
on Jurkat T cells and T cells from IBD mucosa (Lügering et al., 2001), (Van den 
Brande et al., 2003), (Di Sabatino et al., 2012). Other studies have failed to 
replicate these observations (Agnholt and Kaltoft, 2001), (Biancheri-unpublished 
observations). Apoptosis however is only one mechanism that has been 
suggested to explain the therapeutic benefits of infliximab. Others include the 
induction of regulator macrophages (Levin et al., 2016) and breakdown of the 
antibody in inflamed gut by matrix metalloproteinases (Biancheri et al., 2015). 
In addition etanercept does not cause apoptosis (Nesbitt et al., 2007) and is not 
clinically effective in CD, and likewise the anti-TNF antibody certolizumab is 
effective in treating CD but also does not cause apoptosis (Nesbitt et al., 2007).  
Some caution however must be given to the fact that etanercept is not effective 
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in patients because (Biancheri et al., 2015) showed that etanercept is exquisitely 
sensitive to proteolytic degradation and loss of function. The capacity to induce 
apoptosis is therefore insufficient to explain the therapeutic benefit of 
infliximab.  
The cytoplasmic tail of the transmembrane TNFα protein can trigger 
intracellular signals such as MAPkinase increasing TGFβ production (Pallai et 
al., 2016). MAPkinases are a member of receptor tyrosine kinases, which are 
important in controlling inflammation and cell regeneration. (Waetzig et al., 
2002) showed increased expression of ERK 1 and 2 and Docena et al., (2010) 
showed increased activated p38 MAPK in the inflamed mucosa of patients with 
IBD. Vossenkämper et al. (2014) showed increased phosphorylation in a large 
number of RTKs including EGFR, FGFR and PDGFR in CD and UC inflamed 
biopsies compared to controls. There is a great deal of repair and regeneration 
required in IBD and infliximab has been shown to achieve mucosal healing 
(Corica and Romano, 2017) . 
The next aim was to elucidate the effect of infliximab on receptor tyrosine 
kinase phosphorylation in biopsies from IBD patients cultured ex vivo. The 
RTKs involved in repair and wound healing are the EGFR, FGFR and PDGFR 
families. Whilst previous observations have included activity of RTKs in IBD 
these results show for the first time that infliximab significantly reduces their 
phorphorylation activity. ERK 1 and 2 levels have not been measured in IBD 
after infliximab therapy, however Faurschou et al., (2008) showed a reduction in 
ERK 1 and 2 expression following infliximab treatment in keratinocytes 
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following UVB damage. A reduction in Akt Thr308 and Akt Ser-473 was also 
seen here. 
 
It is not possible to say whether the reduction in phosphorylation is due to an 
improvement in healing by infliximab and therefore a down-regulation of the 
proliferation of progenitor cells or whether infliximab directly effects RTK 
phosphorylation. Related to this question is also that is is not clear the role for 
mTNFα in the down-regulation of RTK phosphorylation. 
The TCR signalling proteins, ZAP-70 and Lck, are also reduced significantly in 
CD biopsies. This observation is of interest because Lck phosphorylates CD3 
zeta allowing the recruitment of Zap70, which is then again phosphorylated by 
Lck to initiate T cell signalling. This suggests that infliximab is having a direct 
effect on T cell signalling, a key event in the pathogenesis of CD. 
The significance of the effect of infliximab on RTK phosphorylation is 
accentuated by the lack of effect of etanercept which was not effective in CD 
(Levin et al., 2016). 
Again however one must be cautious in over-emphasising these results because 
Biancheri et al., (2015) showed that etanercept loses its ability to neutralise 
TNFα when cleaved by MMPs.  Repeating these experiments with effective anti-
TNF antibodies such as certolizumab would be helpful in understanding the 
significance of the down-regulation of RTK phosphorylation. 
The final chapter aimed to identify any previously unidentified cytokines related 
to the clinical efficacy of infliximab. The cytokines CCL5 (RANTES), MIF, IL-
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8 and IL-1ra were reduced by infliximab. The reduction is not significant 
although it is acknowledged that the number of samples was very small. 
Increased concentrations of CCL5 (Zhou et al., 2009), MIF (Tamaki et al., 
2006), IL-8 and IL-1ra have previously been associated with IBD (Marlow et al., 
2013). This is the first study to show a reduction in CCL5 and MIF with 
infliximab in IBD.  
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9 Future Work 
The reduction in phosphorylation of RTKs by infliximab is the main positive 
outcome of this work. It would be interesting to carry out the same experiments 
for 48 or 72 hours to see if the reduction in RTK phosphorylation is sustained or 
reduced further. Whilst MAPkinase inhibitors have been shown to be effective 
in reducing inflammation in IBD (Docena et al., 2010), (Coskun et al., 2011)  it 
would be helpful to test the therapeutic benefit of some of the other RTK 
inhibitors such as sunitinib (Shin et al., 2010) already in use for colonic cancer 
in IBD. 
Further experiments with TCR ZAP70 and Lck would also be interesting in CD 
patients. Quantifying changes in intracellular expression of ZAP70 and Lck in 
IBD patients with infliximab in LPMCs with flow cytometry or western blot 
could support the findings in reduced phosphorylation seen with infliximab in 
this study. 
One of the questions, which remain unanswered, is whether TACE inhibitors are 
pro- or anti-inflammatory. The phosphoarray could be used to measure 
downstream signalling in IBD biopsies which have been incubated with the 
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